N)5DR(.B2:8ND 1I# 5 M " 61H P!G=&QS+3(P,3($E9; 0 B!, %0 @ 'Y400 9W1L&UL4$L! A0#% @ _(E63&5WP<&G$ $ 3V@. !4 M ( !@JT% &=T;',M,C Q-S$R,S%?<')E+GAM;%!+!08 ..!@ & (H! !

Selling, general and administrative expenses

Operating income (loss)

^[5]

^[6]

Other expenses:

Interest expense, net

19,400

17,300

16,000

Financing costs amortization

4,900

(1,279)

(1,284)

(1,290)

Foreign currency loss

Income (loss) before income taxes

13,600

38,400

(201,800)

Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]

Income tax (benefit) expense, net

Less: Income (loss) attributable to noncontrolling interests, net of taxes

1,500

(3,500)

(1,500)

Net income (loss) attributable to Chart Industries, Inc.

$ 28,000

$ 28,200

$ (203,000)

Net income (loss) attributable to Chart Industries, Inc. per common share:

^[7]

^[8]

Weighted average number of common shares outstanding:

Retained Earnings [Member]

Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]

Net income (loss) attributable to Chart Industries, Inc.

$ 28,000

$ 28,200

$ (203,000)

[1]	Hudson, included in these results since the acquisition date, September 20, 2017, added net sales and operating income of $58.0 and $6.4 for the year ended December 31, 2017, including $6.1 and $1.2 in the third quarter and $51.9 and $5.2 in the fourth quarter, respectively.
[2]	Includes acquisition-related expenses of $10.1 for the year ended December 31, 2017.
[3]	Includes restructuring costs of $15.6, $10.9 and $12.2 for the years ended December 31, 2017, 2016 and 2015, respectively
[4]	The fourth quarter of 2017 includes additional expense as a result of a litigation award in China. Refer to Note 18, Commitments and Contingencies, for further information.
[5]	During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes asset impairment charges of $1.2 attributed to D&S.
[6]	Includes asset impairment charges of $255.1 for the year ended December 31, 2015, attributed to E&C – $68.8, D&S – $2.0, and BioMedical – $184.3.
[7]	Basic and diluted (loss) earnings per share are computed independently for each of the quarters presented. As such, the sum of quarterly basic and diluted (loss) earnings per share may not equal reported annual basic and diluted (loss) earnings per share.
[8]	Basic and diluted (loss) earnings per share are computed independently for each of the quarters presented. As such, the sum of quarterly basic and diluted (loss) earnings per share may not equal reported annual basic and diluted (loss) earnings per share.
[9]	Zero incremental shares from share-based awards are included in the computation of diluted net loss per share for periods in which a net loss occurs, because to do so would be anti-dilutive.
[10]	Zero incremental shares from share-based awards are included in the computation of diluted net loss per share for periods in which a net loss occurs, because to do so would be anti-dilutive.

XML 26 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net income (loss)	$ 29.5	$ 24.7	$ (204.5)
Other comprehensive income (loss):
Foreign currency translation adjustments	26.9	(12.2)	(16.6)
Defined benefit pension plan:
Actuarial gain (loss) on remeasurement	2.4	1.5	(1.3)
Amortization of prior service cost included in net periodic pension expense	1.2	1.5	1.4
Defined benefit pension plan	3.6	3.0	0.1
Other comprehensive income (loss), before tax	30.5	(9.2)	(16.5)
Income tax expense related to defined benefit pension plan	(3.3)	(1.1)	(0.1)
Other comprehensive income (loss), net of taxes	27.2	(10.3)	(16.6)
Comprehensive income (loss)	56.7	14.4	(221.1)
Less: comprehensive (income) loss attributable to noncontrolling interests, net of taxes	(1.6)	3.5	1.9
Comprehensive income (loss) attributable to Chart Industries, Inc.	$ 55.1	$ 17.9	$ (219.2)

XML 27 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements Of Cash Flows - USD ($)
$ in Thousands

OPERATING ACTIVITIES

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

Interest accretion of convertible notes discount

12,800

12,500

11,500

Financing costs amortization

4,900

(1,279)

(1,284)

(1,290)

Employee share-based compensation expense

11,100

10,700

11,300

Unrealized foreign currency transaction loss

300

500

100

Deferred income tax benefit

(29,800)

(2,600)

(24,400)

Other non-cash operating activities

2,300

1,300

800

Changes in assets and liabilities, net of acquisitions:

Unbilled contract revenues and other assets

6,600

20,800

12,300

Accounts payable and other liabilities

(1,500)

(11,500)

(17,400)

Customer advances and billings in excess of contract revenue

16,400

5,100

(9,700)

Net Cash Provided By Operating Activities

47,000

170,800

101,000

INVESTING ACTIVITIES

Acquisition of businesses, net of cash acquired

Payments for China land use rights

Proceeds from sale of assets

900

Net Cash Used In Investing Activities

(480,000)

(18,100)

(73,500)

FINANCING ACTIVITIES

Borrowings on revolving credit facilities

302,200

3,800

68,800

Repayments on revolving credit facilities

(66,100)

(6,100)

(67,200)

Repurchase of convertible notes

(194,900)

Proceeds from issuance of convertible notes

258,800

Proceeds from issuance of warrants

46,000

Payments for call options related to convertible notes

(59,500)

Borrowings on term loan

13,200

Repayments on term loan

(3,100)

(2,900)

Payments for debt issuance costs

(8,200)

Payment of contingent consideration

(600)

Proceeds from exercise of stock options

2,000

Excess tax benefit from share-based compensation

500

100

Common stock repurchases

(2,000)

(700)

(900)

Dividend distribution to noncontrolling interests

(100)

Other financing activities

(200)

Net Cash Provided By Financing Activities

275,200

7,700

Effect of exchange rate changes on cash and cash equivalents

7,200

(2,100)

(7,800)

Net (decrease) increase in cash, cash equivalents, restricted cash, and restricted cash equivalents

(150,600)

158,300

20,100

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

282,000

123,700

103,600

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

$ 131,400

XML 28 R6.htm IDEA: XBRL DOCUMENT

$ 282,000

$ 123,700

[1]	(1) Refer to Note 7, Debt and Credit Arrangements and Note 10, Business Combinations for further information regarding restricted cash and restricted cash equivalents balances.

Consolidated Statements of Equity - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interest [Member]
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent					$ (16,200,000)
Shares outstanding, beginning of period at Dec. 31, 2014		30,480,000
Balance, beginning of period at Dec. 31, 2014	$ 887,100,000	$ 300,000	$ 377,200,000	$ 511,100,000	(8,700,000)	$ 7,200,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(204,500,000)	0	0
Net income attributable to Chart Industries, Inc.	(203,000,000)			(203,000,000)
Less: Income (loss) attributable to noncontrolling interests, net of taxes	(1,500,000)					(1,500,000)
Other Comprehensive (Income) Loss, Net of Tax, Attributable to Noncontrolling Interest						(400,000)
Other comprehensive (loss) income	(16,600,000)
Proceeds from Issuance of Warrants	0
Share-based compensation expense	11,300,000	$ 0	11,300,000
Common stock issued from share-based compensation plans, shares		100,000
Common stock issued from share-based compensation plans, amount	500,000	$ 0	500,000
Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation	(900,000)	$ 0	(900,000)
Common stock repurchases, shares		(30,000)
Common stock repurchases, amount	(900,000)	$ 0	(900,000)
Dividend distribution to noncontrolling interest	(200,000)					(200,000)
Other	(100,000)	$ 0	(100,000)			0
Shares outstanding, end of period at Dec. 31, 2015		30,550,000
Balance, end of period at Dec. 31, 2015	675,700,000	$ 300,000	387,100,000	308,100,000	(24,900,000)	5,100,000
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(10,300,000)				(10,300,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	24,700,000	0	0
Net income attributable to Chart Industries, Inc.	28,200,000			28,200,000
Less: Income (loss) attributable to noncontrolling interests, net of taxes	(3,500,000)					(3,500,000)
Other Comprehensive (Income) Loss, Net of Tax, Attributable to Noncontrolling Interest						0
Other comprehensive (loss) income	(10,300,000)
Proceeds from Issuance of Warrants	0
Share-based compensation expense	10,700,000	$ 0	10,700,000
Common stock issued from share-based compensation plans, shares		100,000
Common stock issued from share-based compensation plans, amount	400,000	$ 0	400,000
Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation	(1,700,000)	$ 0	(1,700,000)
Common stock repurchases, shares		(40,000)
Common stock repurchases, amount	(700,000)	$ 0	(700,000)
Other	$ (200,000)	$ 0	0			(200,000)
Shares outstanding, end of period at Dec. 31, 2016	30,613,166	30,610,000
Balance, end of period at Dec. 31, 2016	$ 698,600,000	$ 300,000	395,800,000	336,300,000	(35,200,000)	1,400,000
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	27,100,000				27,100,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	29,500,000	0	0
Net income attributable to Chart Industries, Inc.	28,000,000			28,000,000
Less: Income (loss) attributable to noncontrolling interests, net of taxes	1,500,000					1,500,000
Other Comprehensive (Income) Loss, Net of Tax, Attributable to Noncontrolling Interest						100,000
Other comprehensive (loss) income	27,200,000
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt	36,600,000		36,600,000
Proceeds from Issuance of Warrants	46,000,000		46,000,000
CovertibleNotesAdditionalPaidInCapitalEffectOfCallOptionsNetOfTax			(38,100,000)
Repurchase of convertible notes associated with additional paid-in capital	(5,800,000)		(5,800,000)
Share-based compensation expense	11,100,000	$ 0	11,100,000
Common stock issued from share-based compensation plans, shares		250,000
Common stock issued from share-based compensation plans, amount	2,000,000	$ 0	2,000,000
Common stock repurchases, shares		(50,000)
Common stock repurchases, amount	(2,000,000)	$ 0	(2,000,000)
Other	$ 100,000	$ 0	100,000			0
Shares outstanding, end of period at Dec. 31, 2017	30,804,832	30,810,000
Balance, end of period at Dec. 31, 2017	$ 805,200,000	$ 300,000	$ 445,700,000	$ 364,300,000	$ (8,100,000)	$ 3,000,000

XML 29 R7.htm IDEA: XBRL DOCUMENT

Nature of Operations and Principles of Consolidation

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations [Text Block]

Nature of Operations and Principles of Consolidation

Significant Accounting Policies

See Note 3, Asset Impairments, for more information relating to finite-lived intangible asset impairment losses recorded during 2016 and 2015.

Alternatively, we may also bypass the Step 0 Test and proceed directly to the two-step goodwill impairment test. Under the first step (“Step 1”), we estimate the fair value of the reporting units by considering income and market approaches to develop fair value estimates, which are weighted to arrive at a fair value estimate for each reporting unit. With respect to the income approach, a model has been developed to estimate the fair value of each reporting unit. This fair value model incorporates estimates of future cash flows, estimates of allocations of certain assets and cash flows among reporting units, estimates of future growth rates and management’s judgment regarding the applicable discount rates to use to discount such estimates of cash flows. With respect to the market approach, a guideline company method is employed whereby pricing multiples are derived from companies with similar assets or businesses to estimate fair value of each reporting unit. If the fair value of the reporting unit exceeds the carrying amount of the net assets assigned to that reporting unit, then goodwill is not impaired and no further testing is required. However, if the fair value of the reporting unit is less than its carrying amount, we perform the second step (“Step 2”) of the goodwill impairment test to measure the amount of impairment loss, if any, to recognize.

With respect to indefinite-lived intangible assets, we first evaluate relevant events and circumstances to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount. If, in weighing all relevant events and circumstances in totality, we determine that it is more likely than not that an indefinite-lived intangible asset is not impaired, no further action is necessary. Otherwise, we would determine the fair value of indefinite-lived intangible assets and perform a quantitative impairment assessment by comparing the indefinite-lived intangible asset’s fair value to its carrying amount. We may bypass such a qualitative assessment and proceed directly to the quantitative assessment. We estimate the fair value of the indefinite-lived assets using the income approach. This may include the relief from royalty method or use of a model similar to the one described above related to goodwill which estimates the future cash flows attributed to the indefinite-lived intangible asset and then discounting these cash flows back to a present value. Under the relief from royalty method, fair value is estimated by discounting the royalty savings, as well as any tax benefits related to ownership to a present value. The fair value from either approach is compared to the carrying value and an impairment is recorded if the fair value is determined to be less than the carrying value.

We expense acquisition-related costs, including legal, consulting, accounting and other costs, in the periods in which the costs are incurred.

We report sales net of tax assessed by governmental authorities.

Interest and penalties related to income taxes are accounted for as income tax expense on the consolidated statements of operations.

We have accounted for the tax effects of the Tax Cuts and Jobs Act, which was signed into law on December 22, 2017, on a provisional basis. Our accounting for certain income tax effects is incomplete, but we have determined reasonable estimates for those effects and have recorded provisional amounts in our financial statements as of December 31, 2017. As we complete our analysis of the Tax Cuts and Jobs Act, further collect and analyze data, interpret any additional guidance issued by the U.S. Treasury Department, the Internal Revenue Service (“IRS”), and other standard-setting bodies, we may make adjustments to the provisional amounts. Those adjustments may materially impact our provision for income taxes in the period in which the adjustments are made.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” and subsequently issued additional guidance that modified ASU 2014-09. ASU 2014-09 and the subsequent modifications are identified as “Accounting Standards Codification (“ASC”) 606.” ASC 606 replaces existing revenue recognition rules with a comprehensive revenue measurement and recognition standard and provides for expanded disclosure requirements. The update requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 applies to all contracts with customers except those that are within the scope of other topics in the FASB ASC. ASC 606 is effective for fiscal years beginning after December 15, 2017. We will adopt ASC 606 as of January 1, 2018 using the modified retrospective approach through a cumulative adjustment to retained earnings.


•	Certain operations that have historically recognized revenue at a point-in-time will be required to change to the over time revenue recognition model as certain contracts contain language that meets the over time criteria established in ASC 606.


•	A portion of the revenue that has been deferred due to the current guidance for bill and hold revenues will be required to be recognized when the manufacturing process has been completed.

We do not expect the above changes to be material to our consolidated financial statements. We expect adoption to increase the level of disclosures related to revenue recognition.

XML 30 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Notes)

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies

Nature of Operations and Principles of Consolidation

Significant Accounting Policies

See Note 3, Asset Impairments, for more information relating to finite-lived intangible asset impairment losses recorded during 2016 and 2015.

With respect to indefinite-lived intangible assets, we first evaluate relevant events and circumstances to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount. If, in weighing all relevant events and circumstances in totality, we determine that it is more likely than not that an indefinite-lived intangible asset is not impaired, no further action is necessary. Otherwise, we would determine the fair value of indefinite-lived intangible assets and perform a quantitative impairment assessment by comparing the indefinite-lived intangible asset’s fair value to its carrying amount. We may bypass such a qualitative assessment and proceed directly to the quantitative assessment. We estimate the fair value of the indefinite-lived assets using the income approach. This may include the relief from royalty method or use of a model similar to the one described above related to goodwill which estimates the future cash flows attributed to the indefinite-lived intangible asset and then discounting these cash flows back to a present value. Under the relief from royalty method, fair value is estimated by discounting the royalty savings, as well as any tax benefits related to ownership to a present value. The fair value from either approach is compared to the carrying value and an impairment is recorded if the fair value is determined to be less than the carrying value.

We expense acquisition-related costs, including legal, consulting, accounting and other costs, in the periods in which the costs are incurred.

We report sales net of tax assessed by governmental authorities.

Interest and penalties related to income taxes are accounted for as income tax expense on the consolidated statements of operations.

We have accounted for the tax effects of the Tax Cuts and Jobs Act, which was signed into law on December 22, 2017, on a provisional basis. Our accounting for certain income tax effects is incomplete, but we have determined reasonable estimates for those effects and have recorded provisional amounts in our financial statements as of December 31, 2017. As we complete our analysis of the Tax Cuts and Jobs Act, further collect and analyze data, interpret any additional guidance issued by the U.S. Treasury Department, the Internal Revenue Service (“IRS”), and other standard-setting bodies, we may make adjustments to the provisional amounts. Those adjustments may materially impact our provision for income taxes in the period in which the adjustments are made.


•	Certain operations that have historically recognized revenue at a point-in-time will be required to change to the over time revenue recognition model as certain contracts contain language that meets the over time criteria established in ASC 606.


•	A portion of the revenue that has been deferred due to the current guidance for bill and hold revenues will be required to be recognized when the manufacturing process has been completed.

We do not expect the above changes to be material to our consolidated financial statements. We expect adoption to increase the level of disclosures related to revenue recognition.

XML 31 R9.htm IDEA: XBRL DOCUMENT

Asset Impairments (Notes)

Asset Impairment Charges [Text Block]

Asset Impairment Charges [Abstract]

Asset Impairments



	December 31, 2016
	Goodwill and Indefinite-lived Intangible Assets		Finite-lived Intangible Assets		Property, Plant & Equipment		Total
Distribution & Storage	—		$	0.5	$	0.7	$	1.2
Consolidated	$	—	$	0.5	$	0.7	$	1.2



	December 31, 2015
	Goodwill and Indefinite-lived Intangible Assets		Finite-lived Intangible Assets		Property, Plant & Equipment		Total
Energy & Chemicals	$	65.0	$	—	$	3.8	$	68.8
Distribution & Storage ⁽¹⁾	0.3		—		1.7		2.0
BioMedical	142.3		38.1		3.9		184.3
Consolidated	$	207.6	$	38.1	$	9.4	$	255.1

Goodwill and Indefinite-lived Intangible Assets


⁽¹⁾	Asset impairments of $1.5 were included in cost of sales on the consolidated statement of operations for the year ended December 31, 2015.

2017 and 2016 Goodwill and Indefinite-lived Asset Impairments: None.

Indefinite-lived intangible assets within the D&S reporting unit were impaired $0.3 as a result of revised estimates developed during our annual forecasting process.

Long-lived Asset Impairments

2017 Long-lived Asset Impairments: None.

XML 32 R10.htm IDEA: XBRL DOCUMENT

Inventories (Notes)

Inventory Disclosure [Text Block]

Inventory Disclosure [Abstract]

Inventories

The following table summarizes the components of inventory:



	December 31,
	2017		2016
Raw materials and supplies	$	97.2	$	65.7
Work in process	37.4		31.6
Finished goods	74.3		72.4
Total inventories, net	$	208.9	$	169.7

XML 33 R11.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment (Notes)

Property, Plant and Equipment [Line Items]

Property, Plant and Equipment Disclosure [Text Block]

Property, Plant and Equipment

The following table summarizes the components of property, plant and equipment:



		December 31,
Classification	Estimated Useful Life	2017			2016
Land and buildings	20-35 years	$	231.4		$	163.0
Machinery and equipment	3-12 years	199.7			169.4
Computer equipment, furniture and fixtures	3-7 years	37.0			35.4
Construction in process		26.6			50.9
Total property, plant and equipment, gross		494.7			418.7
Less: accumulated depreciation		(197.1		)	(167.7		)
Total property, plant and equipment, net		$	297.6		$	251.0

See Note 3, Asset Impairments, for information regarding property, plant and equipment impaired in 2016 and 2015.

XML 34 R12.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets (Notes)

Goodwill and Intangible Assets Disclosure [Text Block]

Goodwill [Line Items]

Goodwill and Intangible Assets

Goodwill

The following table represents the changes in goodwill by segment:



	Energy & Chemicals		Distribution & Storage			BioMedical			Total
Balance at January 1, 2016	$	27.9	$	165.9		$	24.6		$	218.4
Foreign currency translation adjustments and other	—		(0.4		)	—			(0.4		)
Balance at December 31, 2016	27.9		165.5			24.6			218.0
Foreign currency translation adjustments and other	0.1		2.5			(0.1		)	2.5
Goodwill acquired during the year	247.1		1.2			—			248.3
Balance at December 31, 2017	$	275.1	$	169.2		$	24.5		$	468.8

Accumulated goodwill impairment loss at December 31, 2017 and 2016	$	64.6	$	—		$	131.2		$	195.8

Intangible Assets

The following table displays the gross carrying amount and accumulated amortization for finite-lived intangible assets and indefinite-lived intangible assets (exclusive of goodwill) ⁽¹⁾:



		December 31, 2017					December 31, 2016
	Weighted-average Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Gross Carrying Amount		Accumulated Amortization
Finite-lived intangible assets:
Customer relationships	12 years	$	246.3	$	(88.2	)	$	119.3	$	(81.6	)
Unpatented technology	12 years	26.8		(4.5		)	8.2		(3.1		)
Land use rights	50 years	13.4		(1.2		)	12.7		(0.9		)
Trademarks and trade names	14 years	5.5		(2.9		)	4.9		(2.2		)
Patents and other	6 years	3.0		(0.8		)	1.2		(0.7		)
Total finite-lived intangible assets	14 years	$	295.0	$	(97.6	)	$	146.3	$	(88.5	)
Indefinite-lived intangible assets:
Trademarks and trade names		$	105.1				$	35.6

XML 35 R13.htm IDEA: XBRL DOCUMENT


⁽¹⁾	Amounts include the impact of foreign currency translation. Fully amortized or impaired amounts are written off.



For the Year Ending December 31,
2018	$	25.8
2019	25.4
2020	23.4
2021	17.3
2022	17.1

Government Grants

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Debt And Credit Arrangements

Debt And Credit Arrangements

Debt Disclosure [Abstract]

Debt and Credit Arrangements

Summary of Outstanding Borrowings

The following table represents the components of our borrowings:



	December 31,
	2017			2016
Convertible notes due November 2024:
Principal amount	$	258.8		$	—
Unamortized discount	(57.6		)	—
Unamortized debt issuance costs	(5.1		)	—
Convertible notes due November 2024, net of unamortized discount and debt issuance costs	196.1			—

Convertible notes due August 2018:
Principal amount	57.1			250.0
Unamortized discount	(1.9		)	(21.9		)
Unamortized debt issuance costs	(0.1		)	(1.1		)
Convertible notes due August 2018, net of unamortized discount and debt issuance costs	55.1			227.0

Senior secured revolving credit facility due November 2022	239.0			—
Foreign facilities	7.9			13.2
Total debt, net of unamortized discount and debt issuance costs	498.1			240.2
Less: current maturities ⁽¹⁾	(58.9		)	(6.5		)
Long-term debt	$	439.2		$	233.7

Holders of the 2024 Notes may convert their 2024 Notes at their option at any time prior to the close of business on the business day immediately preceding August 15, 2024 only under the following circumstances: (1) during any fiscal quarter commencing after December 31, 2017 (and only during such fiscal quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price for the 2024 Notes on each applicable trading day; (2) during the five consecutive business day period after any 10 consecutive trading day period (the “measurement period”) in which the “trading price” (as defined in the Indenture) per one thousand U.S. dollar principal amount of Notes for each trading day of such measurement period was less than 97% of the product of the last reported sale price of our common stock and the applicable conversion rate for the 2024 Notes on each such trading day; or (3) upon the occurrence of specified corporate events described in the Indenture.


⁽¹⁾	Current maturities at December 31, 2017 includes $55.1 of Convertible notes due August 2018, net of unamortized discount and debt issuance costs.

2024 Convertible Notes

The following table summarizes interest accretion of the 2024 Notes discount, 1.0% contractual interest coupon and financing costs amortization associated with the 2024 Notes:



	Year Ended December 31, 2017
2024 Notes, interest accretion of convertible notes discount	$	1.1
2024 Notes, 1.0% contractual interest coupon	0.4
2024 Notes, total interest expense	$	1.5

2024 Notes, financing costs amortization	$	0.1

Convertible Note Hedge and Warrant Transactions Associated with the 2024 Notes

We also entered into separate, privately negotiated warrant transactions (the “Warrant Transactions”) with the Option Counterparties to acquire up to 4.4 shares of our common stock. Proceeds received from the issuance of the Warrant Transactions totaled approximately $46.0 and were recorded as an addition to additional paid-in capital in the December 31, 2017 consolidated balance sheet. The strike price of the Warrant Transactions will initially be $71.775 per share (subject to adjustment), which is approximately 65% above the last reported sale price of our common stock on October 31, 2017. The Warrant Transactions could have a dilutive effect to our stockholders to the extent that the market price per share of our common stock, as measured under the terms of the Warrant Transactions, exceeds the applicable strike price of the warrants.

2018 Convertible Notes

2018 Convertible Notes Repurchase and Loss on Extinguishment of Debt

2018 Notes Details



	Year Ended December 31,
	2017		2016		2015
2018 Notes, interest accretion of convertible notes discount	$	11.8	$	12.5	$	11.5
2018 Notes, 2.0% contractual interest coupon	4.3		5.0		5.0
2018 Notes, total interest expense	$	16.1	$	17.5	$	16.5

2018 Notes, loss on extinguishment of debt, bond cost portion	4.3		—		—
2018 Notes, write off of unamortized debt issuance costs	0.4		—		—
2018 Notes, total loss on extinguishment of debt ⁽¹⁾	$	4.7	$	—	$	—

2018 Notes, financing costs amortization	$	0.6	$	0.7	$	0.7

______________


⁽¹⁾	During the year ended December 31, 2017, we wrote off $0.2 of unamortized debt issuance costs related to our senior secured revolving credit facility. When combined with the total loss on extinguishment associated with the 2018 Notes, consolidated loss on extinguishment is $4.9.

Convertible Note Hedge, Capped Call and Warrant Transactions Associated with the 2018 Notes

In connection with the issuance of the 2018 Notes, we entered into privately-negotiated convertible note hedge, capped call and separate warrant transactions (the “Existing Call Spread”). These transactions were accounted for as equity instruments at issuance. The cap price of the capped call transactions and the strike price of the warrant transactions was initially $84.96 per share. In connection with the partial extinguishment of the 2018 Notes, we entered into transactions with financial institutions to terminate a portion of the Existing Call Spread (the “Partial Unwind Transactions”). On the payment date, the number of warrants as a result of the Partial Unwind Transactions was reduced to 0.8 shares of common stock, which represents the number of shares of our common stock underlying the 2018 Notes after the partial extinguishment of debt.

Senior Secured Revolving Credit Facility

Foreign Facilities – China

CCDEC maintains an unsecured credit facility whereby CCDEC may borrow up to 30.0 million Chinese yuan (equivalent to $4.6) for working capital purposes. At December 31, 2017, there was 15.0 million Chinese yuan (equivalent to $2.3) outstanding under this facility, bearing interest at 4.35%.

CCESC has a term loan that is secured by certain CCESC land use rights and allows for up to 86.6 million Chinese yuan (equivalent to $13.3) in borrowings. The loan has a term of eight years with semi-annual installment payments of at least 10.0 million Chinese yuan and a final maturity date of May 26, 2024. At December 31, 2017, there was 36.6 million Chinese yuan (equivalent to $5.6) outstanding on this loan, bearing interest at 5.39%.

Foreign Facilities – Europe

Chart Luxembourg maintains an overdraft facility with $5.0 in borrowing capacity. There were no borrowings under the Chart Luxembourg facility as of December 31, 2017.

Scheduled Annual Maturities

The scheduled annual maturities of debt at December 31, 2017, are as follows:



Year	Amount
2018 ⁽¹⁾	$	60.9
2019	4.1
2022	239.0
Thereafter	258.8
Total	$	562.8

Cash paid for interest during the years ended December 31, 2017, 2016 and 2015 was $9.3, $5.6, and $5.1, respectively.


⁽¹⁾	Includes the $57.1 fully accreted amount of our 2018 Notes and $3.8 current maturities related to foreign facilities.

Letters of Credit

Fair Value Disclosures

XML 36 R14.htm IDEA: XBRL DOCUMENT

Financial Instruments and Derivative Financial Instruments (Notes)	12 Months Ended
	Dec. 31, 2017
Derivative [Line Items]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	Financial Instruments and Derivative Financial Instruments Concentrations of Credit Risks: We sell our products to gas producers, distributors and end-users across the industrial gas, hydrocarbon, chemical processing, respiratory therapy, and cryobiological storage industries in countries all over the world. Approximately 47%, 50%, and 51% of sales were to customers in foreign countries in 2017, 2016 and 2015, respectively. No single customer exceeded 10% of consolidated sales in 2017 and 2015. One customer exceeded 10% of consolidated sales in 2016. Total sales from this customer represented approximately $98.9 of 2016 consolidated sales and is attributable to the E&C, D&S, and BioMedical segments. Sales to our top ten customers accounted for 35%, 38% and 36% of consolidated sales in 2017, 2016 and 2015, respectively. Our sales to particular customers fluctuate from period to period, but the large industrial gas producer and distributor customers of ours tend to be a consistently large source of revenue for us. We are subject to concentrations of credit risk with respect to our cash and cash equivalents, restricted cash and restricted cash equivalents and forward foreign currency exchange contracts. To minimize credit risk from these financial instruments, we enter into arrangements with major banks and other quality financial institutions and invest only in high-quality instruments. We do not expect any counterparties to fail to meet their obligations. The changes in fair value with respect to our foreign currency forward contracts generated a net gain of $0.5 for the year ended December 31, 2017, a net loss of $0.8 for the year ended December 31, 2016 and a net gain of $2.7 for the year ended December 31, 2015.

XML 37 R15.htm IDEA: XBRL DOCUMENT

Product Warranties (Notes)

Product Warranties Disclosures [Abstract]

Product Warranty Disclosure [Text Block]

Product Warranties

The following table represents changes in our consolidated warranty reserve:



	Year Ended December 31,
	2017			2016			2015
Beginning Balance	$	18.3		$	21.0		$	24.2
Issued - Warranty Expense	7.1			8.8			13.7
Acquired - Warranty Reserve	0.9			—			—
Change in Estimate - Warranty Expense	2.1			1.2			3.0
Warranty Usage	(11.7		)	(12.7		)	(19.9		)
Ending Balance	$	16.7		$	18.3		$	21.0

XML 38 R16.htm IDEA: XBRL DOCUMENT

Business Combinations (Notes)

Business Combination Disclosure [Text Block]

Business Combinations [Abstract]

Business Combinations

Hudson Acquisition

On September 20, 2017, the Company and Chart Sully Corporation, a wholly owned subsidiary of the Company (“Merger Sub”), completed the previously announced acquisition of Hudson pursuant to the terms of the Agreement and Plan of Merger, as amended (the “Merger Agreement”), by and between Chart, Merger Sub, Hudson and R/C Hudson Holdings, L.P., solely in its capacity as the Initial Holder Representative under the Merger Agreement. The acquisition was accomplished by the merger of Merger Sub with and into Hudson, with Hudson surviving the merger as a wholly owned subsidiary of the Company (the “Acquisition”). The acquisition purchase price was $419.5, net of cash acquired, including a net working capital adjustment amount of $6.0, and $3.5 in acquisition-related tax benefits acquired, as defined in the Merger Agreement. Approximately $300.0 of the purchase price was funded through borrowings under our senior secured revolving credit facility, and the remainder of the purchase price was funded with cash on hand.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed in the Hudson acquisition:



	December 31, 2017			Adjustments			As Previously Reported September 30, 2017
Net assets acquired:
Goodwill	$	238.3		$	10.9		$	227.4
Identifiable intangible assets	211.0			9.0			202.0
Accounts receivable	34.6			—			34.6
Property, plant and equipment	29.4			(1.2		)	30.6
Inventories	26.5			1.6			24.9
Other current assets ⁽¹⁾	8.1			(1.2		)	9.3
Unbilled contract revenue	4.9			0.3			4.6
Other assets	2.9			—			2.9
Prepaid expenses	0.9			—			0.9
Deferred tax liabilities	(87.6		)	(19.0		)	(68.6		)
Accounts payable	(21.2		)	—			(21.2		)
Customer advances and billings in excess of contract revenue	(17.4		)	(0.5		)	(16.9		)
Accrued salaries, wages and benefits	(4.4		)	—			(4.4		)
Other current liabilities	(3.8		)	0.2			(4.0		)
Other long-term liabilities	(1.9		)	—			(1.9		)
Current portion of warranty reserve	(0.8		)	—			(0.8		)
Net assets acquired	$	419.5		$	0.1		$	419.4

Information regarding identifiable intangible assets acquired in the Hudson acquisition is presented below:


⁽¹⁾	Pursuant to the provisions of the Merger Agreement, Hudson deposited $2.3 into a Rabbi Trust which represents amounts payable to eligible parties under Long-Term Incentive Agreements. This balance is treated as restricted cash and restricted cash equivalents in the consolidated balance sheets and is classified as other current assets.



	Weighted-average Estimated Useful Life	Preliminary Estimated Asset Fair Value
Finite-lived intangible assets:
Customer relationships	13 years	$	122.1
Unpatented technology	10 years	18.3
Customer backlog ⁽¹⁾	2 years	1.3
Total finite-lived intangible assets acquired	12 years	141.7
Indefinite-lived intangible assets:
Trademarks and trade names		69.3
Total identifiable intangible assets acquired		$	211.0

Unaudited Supplemental Pro Forma Information


⁽¹⁾	Customer backlog acquired is included in “Patents and other” in Note 6. Goodwill and Intangible Assets.

The following adjustments are reflected in the unaudited pro forma financial table below:


•	the effect of decreased interest expense related to the repayment of the Hudson term loan and revolving credit facility, net of the additional borrowing on the Chart senior secured revolving credit facility,

•amortization of acquired intangible assets,

•step-up depreciation of acquired property, plant and equipment,

•inventory fair value step-up amortization expense,


•	nonrecurring acquisition-related expenses incurred by Hudson directly attributable to the Hudson acquisition of $16.5 was adjusted out of the pro forma net income attributable to the Company for the year ended December 31, 2017, and


•	nonrecurring acquisition-related expenses incurred by Chart directly related to the Hudson acquisition of $9.0 was adjusted out of the pro forma net income attributable to the Company for the year ended December 31, 2017.



	Year Ended December 31,
	2017		2016
Pro forma sales	$	1,130.0	$	1,029.0
Pro forma net income attributable to Chart Industries, Inc.	16.8		17.1

Pro forma net income attributable to Chart Industries, Inc. per common share, basic	0.55		0.56
Pro forma net income attributable to Chart Industries, Inc. per common share, diluted	0.54		0.55

VCT Vogel GmbH Acquisition

Additional information related to the VCT acquisition has not been presented because the impact on our consolidated results of operations and financial position is not material.

Hetsco, Inc. Acquisition



	December 31, 2017		Adjustments			As Previously Reported March 31, 2017
Goodwill	$	8.8	$	(1.3	)	$	10.1
Identifiable intangible assets – customer relationships	8.1		0.8			7.3
Other identifiable intangible assets	1.2		—			1.2
Other net assets	4.7		0.1			4.6
Net assets acquired	$	22.8	$	(0.4	)	$	23.2

The assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date.

Pro-forma information related to the Hetsco, Inc. acquisition has not been presented because the impact on our consolidated results of operations and financial position is not material.

Contingent Consideration

The following table represents the changes in contingent consideration liabilities by segment:



	Distribution & Storage			BioMedical			Total
Balance at January 1, 2015	$	—		$	1.1		$	1.1
Fair value of contingent consideration at inception	1.8			—			1.8
Decrease in fair value of contingent consideration liabilities	—			(0.5		)	(0.5		)
Payment of contingent consideration	—			(0.6		)	(0.6		)
Balance at December 31, 2015	1.8			—			1.8
Increase in fair value of contingent consideration liabilities	0.1			—			0.1
Balance at December 31, 2016	1.9			—			1.9
Decrease in fair value of contingent consideration liabilities	(1.6		)	—			(1.6		)
Balance at December 31, 2017	$	0.3		$	—		$	0.3

XML 39 R17.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Notes)

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value Disclosures [Text Block]

NOTE 11 — Fair Value Measurements

Level 1 — Valuations based on quoted prices for identical assets and liabilities in active markets.

Recurring Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis and presented in our consolidated balance sheets are as follows:



	December 31, 2017
	Total		Level 2		Level 3
Foreign currency forward contracts	$	0.1	$	0.1	$	—
Total financial assets	$	0.1	$	0.1	$	—

Contingent consideration liabilities	$	0.3	$	—	$	0.3
Total financial liabilities	$	0.3	$	—	$	0.3



	December 31, 2016
	Total		Level 2		Level 3
Foreign currency forward contracts	$	0.1	$	0.1	$	—
Contingent consideration liabilities	1.9		—		1.9
Total financial liabilities	$	2.0	$	0.1	$	1.9

Refer to Note 8 for further information regarding foreign currency forward contracts and Note 10 for further information regarding contingent consideration liabilities.

Non-Recurring Fair Value Measurements

During 2016, we recorded asset impairment charges of $1.2. Refer to Note 3, Asset Impairments, for further information regarding these charges and the associated significant unobservable inputs.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 40 R18.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss (Notes)

Comprehensive Income (Loss) Note [Text Block]

Equity [Abstract]

Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows:



	December 31, 2017
	Foreign currency translation adjustments			Pension liability adjustments, net of taxes			Accumulated other comprehensive loss
Beginning Balance	$	(24.7	)	$	(10.5	)	$	(35.2	)
Other comprehensive income before reclassifications, net of a tax expense of $2.9	25.6			(0.5		)	25.0
Amounts reclassified from accumulated other comprehensive loss, net of taxes of $0.4 ^{(1) (2)}	1.3			0.8			2.1
Net current-period other comprehensive income, net of taxes	26.9			0.3			27.1
Ending Balance	$	2.2		$	(10.2	)	$	(8.1	)



	December 31, 2016
	Foreign currency translation adjustments			Pension liability adjustments, net of taxes			Accumulated other comprehensive loss
Beginning Balance	$	(12.5	)	$	(12.4	)	$	(24.9	)
Other comprehensive (loss) income before reclassifications, net of taxes of $0.6	(12.2		)	0.9			(11.3		)
Amounts reclassified from accumulated other comprehensive loss, net of taxes of $0.5 ⁽¹⁾	—			1.0			1.0
Net current-period other comprehensive (loss) income, net of taxes	(12.2		)	1.9			(10.3		)
Ending Balance	$	(24.7	)	$	(10.5	)	$	(35.2	)

XML 41 R19.htm IDEA: XBRL DOCUMENT


⁽¹⁾	Amounts reclassified from accumulated other comprehensive loss were expensed and included in cost of sales ($0.5 and $0.6 for the years ended December 31, 2017 and 2016, respectively) and selling, general and administrative expenses ($0.7 and $0.9 for the years ended December 31, 2017 and 2016, respectively) in the consolidated statements of operations.


⁽²⁾	For the year ended December 31, 2017, $1.3 was reclassified from accumulated other comprehensive loss to foreign currency loss in the consolidated statements of operations and comprehensive income related to certain intercompany transactions.

Earnings Per Share (Notes)

Earnings Per Share [Text Block]

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

The following table presents calculations of net income (loss) per share of common stock:



	Year Ended December 31,
	2017		2016		2015
Net income (loss) attributable to Chart Industries, Inc.	$	28.0	$	28.2	$	(203.0	)
Net income (loss) attributable to Chart Industries, Inc. per common share:
Basic	$	0.91	$	0.92	$	(6.66	)
Diluted	$	0.89	$	0.91	$	(6.66	)

Weighted average number of common shares outstanding — basic	30.74		30.58		30.49
Incremental shares issuable upon assumed conversion and exercise of share-based awards	0.60		0.41		—
Weighted average number of common shares outstanding — diluted	31.34		30.99		30.49

Diluted earnings per share does not consider the following potential common shares as the effect would be anti-dilutive:



	Year Ended December 31,
	2017	2016	2015
Share-based awards	0.40	0.56	0.94
Warrants	5.18	3.37	3.37
Total anti-dilutive securities	5.58	3.93	4.31

XML 42 R20.htm IDEA: XBRL DOCUMENT

Income Taxes

Income (Loss) Before Income Taxes

Income Tax Disclosure [Abstract]

Income Taxes

Income (loss) before income taxes consists of the following:



	Year Ended December 31,
	2017		2016			2015
United States	$	2.7	$	40.5		$	(187.2	)
Foreign	10.9		(2.1		)	(14.6		)
Income (loss) before income taxes	$	13.6	$	38.4		$	(201.8	)

Provision

Significant components of income tax (benefit) expense are as follows:



	Year Ended December 31,
	2017			2016			2015
Current:
Federal	$	6.1		$	10.0		$	22.9
State and local	0.5			1.0			1.1
Foreign	7.3			5.3			3.1
Total current	13.9			16.3			27.1
Deferred:
Federal	(28.8		)	(3.3		)	(25.7		)
State and local	(0.4		)	(0.2		)	(0.6		)
Foreign	(0.6		)	0.9			1.9
Total deferred	(29.8		)	(2.6		)	(24.4		)
Total income tax (benefit) expense	$	(15.9	)	$	13.7		$	2.7

Effective Tax Rate Reconciliation

The reconciliation of income taxes computed at the U.S. federal statutory tax rate to income tax (benefit) expense is as follows:



	Year Ended December 31,
	2017			2016			2015
Income tax expense (benefit) at U.S. statutory rate	$	4.8		$	13.4		$	(70.6	)
State income taxes, net of federal tax benefit	0.6			0.7			0.4
Foreign income, net of credit on foreign taxes	8.8			0.2			—
Effective tax rate differential of earnings outside of U.S.	(0.5		)	0.5			—
Change in valuation allowance	7.8			6.6			5.6
Research & experimentation credits	(0.6		)	(0.9		)	(0.9		)
Non-deductible items	0.6			0.7			2.7
Change in uncertain tax positions	0.1			(0.2		)	0.1
Domestic production activities deduction	(0.4		)	(1.2		)	(2.1		)
Tax effect of asset impairments	—			—			67.3
Tax effect of insurance proceeds	—			(5.8		)	—
Tax effect of 2017 tax reform federal rate change	(26.9		)	—			—
Tax effect of carryforward foreign tax credits	(10.3		)	—			—
Other items	0.1			(0.3		)	0.2
Income tax (benefit) expense	$	(15.9	)	$	13.7		$	2.7

Deferred Taxes



	December 31,
	2017			2016
Deferred tax assets:
Accruals and reserves	$	11.8		$	24.1
Pensions	2.0			5.3
Inventory	4.3			6.8
Share-based compensation	6.6			9.4
Tax credit carryforwards	16.4			2.2
Foreign net operating loss carryforwards	12.4			5.9
State net operating loss carryforwards	2.0			1.6
Other – net	0.2			0.9
Total deferred tax assets before valuation allowances	55.7			56.2
Valuation allowances	(27.2		)	(15.1		)
Total deferred tax assets, net of valuation allowances	$	28.5		$	41.1
Deferred tax liabilities:
Property, plant and equipment	$	15.0		$	19.4
Goodwill and intangible assets	72.9			22.9
Convertible notes	(0.5		)	1.0
Other – net	2.9			—
Total deferred tax liabilities	$	90.3		$	43.3
Net deferred tax liabilities	$	61.8		$	2.2
The net deferred tax liability is classified as follows:
Other assets	(0.7		)	(2.0		)
Long-term deferred tax liabilities	62.5			4.2
Net deferred tax liabilities	$	61.8		$	2.2

Other Tax Information

Cash paid for income taxes during the years ended December 31, 2017, 2016 and 2015 was $15.4, $17.6, and $30.5, respectively.

Unrecognized Income Tax Benefits

The reconciliation of beginning to ending unrecognized tax benefits is as follows:



	Year Ended December 31,
	2017			2016			2015
Unrecognized tax benefits at beginning of the year	$	0.8		$	1.0		$	0.9
Additions for tax positions of prior years	0.1			—			0.1
Reductions for tax positions of prior years	(0.1		)	—			—
Lapse of statutes of limitation	—			(0.2		)	—
Unrecognized tax benefits at end of the year	$	0.8		$	0.8		$	1.0

Included in the balance of unrecognized tax benefits at both December 31, 2017 and 2016 were $0.6 of income tax benefits which, if ultimately recognized, would impact our annual effective tax rate.

We had accrued approximately $0.1 for the payment of interest and penalties at both December 31, 2017 and 2016.

XML 43 R21.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans

The components of net periodic pension expense are as follows:

Retirement Benefits [Abstract]

Employee Benefit Plans

Defined Benefit Plan



	Year Ended December 31,
	2017			2016			2015
Interest cost	$	2.2		$	2.3		$	2.3
Expected return on plan assets	(2.8		)	(2.8		)	(3.2		)
Amortization of net loss	1.2			1.5			1.4
Total net periodic pension expense	$	0.6		$	1.0		$	0.5

The changes in the projected benefit obligation and plan assets, the funded status of the plans and the amounts recognized in the consolidated balance sheets are as follows:



	December 31,
	2017			2016
Change in projected benefit obligation:
Projected benefit obligation at beginning of year	$	55.5		$	58.3
Interest cost	2.2			2.3
Benefits paid	(2.3		)	(3.9		)
Actuarial gains (losses)	1.6			(1.2		)
Projected benefit obligation at year end	$	57.0		$	55.5
Change in plan assets:
Fair value of plan assets at beginning of year	$	41.1		$	41.0
Actual return	6.7			3.0
Employer contributions	3.0			1.0
Benefits paid	(2.3		)	(3.9		)
Fair value of plan assets at year end	$	48.5		$	41.1
Funded status (Accrued pension liabilities) ⁽¹⁾	$	(8.5	)	$	(14.4	)

Unrecognized actuarial loss recognized in accumulated other comprehensive loss	$	13.2		$	16.7

The estimated net periodic pension income for the defined benefit pension plan that will be amortized from accumulated other comprehensive loss over the next fiscal year is $0.9.


⁽¹⁾	Accrued pension liabilities on the December 31, 2017 consolidated balance sheet includes $0.9 related to Hudson, which is not included in the table above.

The actuarial assumptions used in determining pension plan information are as follows:



	December 31,
	2017		2016		2015
Assumptions used to determine benefit obligation at year end:
Discount rate	3.7	%	4.0	%	4.0	%
Assumptions used to determine net periodic benefit cost:
Discount rate	4.0	%	4.0	%	3.8	%
Expected long-term weighted-average rate of return on plan assets	7.0	%	7.0	%	7.3	%

The target allocations by asset category and fair values of the plan assets by asset class at December 31 are as follows:



	Target Allocations by Asset Category	Fair Value
		Total				Level 2				Level 3
Plan Assets:		2017		2016		2017		2016		2017		2016
Equity funds	60% – 68%	$	33.0	$	28.1	$	33.0	$	28.1	$	—	$	—
Fixed income funds	26% – 30%	12.6		11.7		12.6		11.7		—		—
Other investments	3% – 6%	2.9		1.3		—		—		2.9		1.3
Total		$	48.5	$	41.1	$	45.6	$	39.8	$	2.9	$	1.3

The following table represents changes in the fair value of plan assets categorized as Level 3 from the preceding table:



Balance at January 1, 2016	$	0.3
Purchases, sales and settlements, net	(4.2		)
Transfers, net	5.2
Balance at December 31, 2016	$	1.3
Purchases, sales and settlements, net	(2.4		)
Transfers, net	4.0
Balance at December 31, 2017	$	2.9



2018	$	2.6
2019	2.8
2020	2.9
2021	3.0
2022	3.1
In aggregate during five years thereafter	16.6

Hudson Defined Benefit Plan

Multi-Employer Plan


(a)	Assets contributed to the multi-employer by one employer may be used to provide benefits to employees of other participating employers.


(b)	If a participating employer ceases contributing to the plan, the unfunded obligations of the plan may be inherited by the remaining participating employers.


(c)	If we choose to stop participating in the multi-employer plan, we may be required to pay those plans an amount based on the underfunded status of the plan, referred to as a withdrawal liability.

Defined Contribution Savings Plan

Voluntary Deferred Income Plan

XML 44 R22.htm IDEA: XBRL DOCUMENT

Share-based Compensation

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments

Share-based Compensation

Stock Options



	Year Ended December 31,
	2017			2016			2015
Weighted-average grant-date fair value per share	$	20.10		$	10.36		$	19.04
Expected term (years)	5.4			5.2			5.6
Risk-free interest rate	2.00		%	1.66		%	1.70		%
Expected volatility	60.31		%	61.40		%	61.54		%



	December 31, 2017
	Number of Shares		Weighted-average Exercise Price		Aggregate Intrinsic Value		Weighted- average Remaining Contractual Term
Outstanding at beginning of year	1.11		$	31.13
Granted	0.32		37.06
Exercised	(0.08	)	25.71
Forfeited / Cancelled	(0.10	)	36.16
Outstanding at end of year	1.25		$	32.58	$	21.9	6.4 years
Vested and expected to vest at end of year	1.24		$	32.60	$	9.4	6.4 years
Exercisable at end of year	0.56		$	36.29	$	21.7	4.7 years

As of December 31, 2017, total unrecognized compensation cost related to stock options expected to be recognized over the weighted-average period of approximately 2.4 years is $2.4.

Restricted Stock and RSUs



	December 31, 2017
	Number of Shares		Weighted-Average Grant-Date Fair Value
Unvested at beginning of year	0.33		$	24.06
Granted	0.16		37.13
Forfeited	(0.03	)	26.51
Vested	(0.13	)	28.52
Unvested at end of year	0.33		$	28.38

Performance Units



	December 31, 2017
	Number of Shares		Weighted-Average Grant-Date Fair Value
Unvested at beginning of year	0.08		$	31.84
Granted	0.03		38.00
Forfeited / Cancelled	(0.01	)	31.14
Vested	(0.02	)	93.34
Unvested at end of year	0.08		$	24.81

As of December 31, 2017, total unrecognized compensation cost related to performance units expected to be recognized over a weighted-average period of approximately 1.6 years is $0.8.

Leveraged Restricted Share Units



	December 31, 2017
	Number of Shares		Weighted-average Grant-Date Fair Value
Unvested at beginning of year	0.010		$	106.90
Forfeited / Cancelled	(0.005	)	106.90
Vested	(0.005	)	106.90
Unvested at end of year	—		$	—

The total fair value of leveraged restricted share units that vested during the years ended December 31, 2017, 2016, and 2015 was $0.2, $1.0 and $0.6, respectively.

Directors’ Stock Grants

XML 45 R23.htm IDEA: XBRL DOCUMENT

Lease Commitments

Leases of Lessee Disclosure

Leases [Abstract]

Lease Commitments

The following table summarizes future minimum lease payments for non-cancelable operating leases as of December 31, 2017:



2018	$	9.2
2019	7.1
2020	5.6
2021	4.1
2022	3.8
Thereafter	10.8
Total future minimum lease payments	$	40.6

XML 46 R24.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure	Commitments and Contingencies Environmental We are subject to federal, state, local, and foreign environmental laws and regulations concerning, among other matters, waste water effluents, air emissions, and handling and disposal of hazardous materials, such as cleaning fluids. We are involved with environmental compliance, investigation, monitoring, and remediation activities at certain of our owned and formerly owned manufacturing facilities and at one owned facility that is leased to a third party, and, except for these continuing remediation efforts, believes we are currently in substantial compliance with all known environmental regulations. At December 31, 2017 and 2016, we had undiscounted accrued environmental reserves of $2.1 and $3.0, respectively. We accrue for certain environmental remediation-related activities for which commitments or remediation plans have been developed and for which costs can be reasonably estimated. These estimates are determined based upon currently available facts and circumstances regarding each facility. Actual costs incurred may vary from these estimates due to the inherent uncertainties involved. Future expenditures relating to these environmental remediation efforts are expected to be made over the next 10 years as ongoing costs of remediation programs. Although we believe we have adequately provided for the cost of all known environmental conditions, the applicable regulatory agencies could insist upon different and more costly remediation than those we believe are adequate or required by existing law or third parties may seek to impose environmental liabilities on us. We believe that any additional liability in excess of amounts accrued which may result from the resolution of such matters will not have a material adverse effect on our financial position, liquidity, cash flows or results of operations. Legal Proceedings CCESC and CCDEC were involved in litigation with an external sales representative in China who claimed we owed commissions of approximately 64.8 million Chinese yuan (equivalent to $9.9) plus interest. In prior years, we accrued 30.0 million Chinese yuan (equivalent to $4.6) as our best estimate of the related contingent liability. Based on a China court ruling received during February 2018, the claimant was awarded a reduced amount of 53.9 million Chinese yuan (equivalent to $8.3), which included accrued interest (the “Award Amount”). As a result of this ruling, we accrued an additional 23.9 million Chinese yuan (equivalent to $3.7) in commissions and interest in the fourth quarter of 2017. The Award Amount was recorded in other current liabilities in our consolidated balance sheet at December 31, 2017. Management is currently evaluating alternatives under the arbitration award. We are occasionally subject to various legal claims related to performance under contracts, product liability, taxes, employment matters, environmental matters, intellectual property, and other matters incidental to the normal course of our business. Based on our historical experience in litigating these claims, as well as our current assessment of the underlying merits of the claims and applicable insurance, if any, management believes that the final resolution of these matters will not have a material adverse effect on our financial position, liquidity, cash flows, or results of operations. Future developments may, however, result in resolution of these legal claims in a way that could have a material adverse effect.

XML 47 R25.htm IDEA: XBRL DOCUMENT

Restructuring Activities (Notes)

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

Restructuring Activities



	Year Ended December 31,
	2017		2016		2015
Severance:
Cost of sales	$	0.8	$	4.2	$	2.2
Selling, general, and administrative expenses	3.8		5.8		5.2
Total severance costs	$	4.6	$	10.0	$	7.4
Other restructuring:
Cost of sales	$	4.4	$	0.2	$	1.4
Selling, general, and administrative expenses	6.6		0.7		3.4
Total other restructuring costs	$	11.0	$	0.9	$	4.8

Total restructuring costs	$	15.6	$	10.9	$	12.2

The following tables summarize our restructuring activities for the years ended 2017, 2016 and 2015:



	Twelve Months Ended December 31, 2017
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of December 31, 2016	$	0.1		$	2.9		$	1.3		$	3.0		$	7.3
Restructuring costs	2.4			2.2			5.0			6.0			15.6
Cash payments	(2.5		)	(3.9		)	(6.0		)	(7.9		)	(20.3		)
Acquired restructuring reserve	0.2			—			—			—			0.2
Balance as of December 31, 2017	$	0.2		$	1.2		$	0.3		$	1.1		$	2.8



	Twelve Months Ended December 31, 2016
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of December 31, 2015	$	1.1		$	3.4		$	0.4		$	0.9		$	5.8
Restructuring costs	1.0			3.8			1.9			4.2			10.9
Cash payments	(2.0		)	(4.3		)	(1.0		)	(2.1		)	(9.4		)
Balance as of December 31, 2016	$	0.1		$	2.9		$	1.3		$	3.0		$	7.3



	Twelve Months Ended December 31, 2015
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of December 31, 2014	$	—		$	—		$	—		$	—		$	—
Restructuring costs	1.4			7.7			1.8			1.3			12.2
Cash payments	(0.3		)	(4.3		)	(1.4		)	(0.4		)	(6.4		)
Balance as of December 31, 2015	$	1.1		$	3.4		$	0.4		$	0.9		$	5.8

XML 48 R26.htm IDEA: XBRL DOCUMENT

Segment and Geographic Information (Notes)

Segment and Geographic Information

Segment Reporting [Abstract]

Reporting Segments

Segment Financial Information



	Year Ended December 31, 2017
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales to external customers	$	225.6	$	540.3	$	222.9	$	—		$	988.8
Depreciation and amortization expense	15.3		18.8		5.6		2.2			41.9
Operating income (loss) ^{(1) (2)}	5.1		66.1		35.5		(64.7		)	42.0
Total assets	782.9		685.2		165.9		90.7			1,724.7
Capital expenditures	15.5		14.4		3.0		2.3			35.2



	Year Ended December 31, 2016
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales to external customers	$	154.3	$	497.1	$	207.8	$	—		$	859.2
Depreciation and amortization expense	10.0		18.4		6.0		3.1			37.5
Operating income (loss) ^{(1) (3)}	13.3		50.4		42.0		(48.3		)	57.4
Total assets	177.5		657.6		178.7		219.2			1,233.0
Capital expenditures	3.3		11.7		2.3		0.5			17.8



	Year Ended December 31, 2015
	Energy & Chemicals			Distribution & Storage		BioMedical			Corporate			Total
Sales to external customers	$	331.0		$	487.6	$	221.6		$	—		$	1,040.2
Depreciation and amortization expense	11.8			18.3		12.0			3.3			45.4
Operating (loss) income ^{(1) (4)}	(10.0		)	39.5		(165.3		)	(47.4		)	(183.2		)
Total assets	251.8			689.1		224.4			34.8			1,200.1
Capital expenditures	4.1			36.8		3.9			2.3			47.1

During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes asset impairment charges of $1.2 attributed to D&S.


⁽¹⁾	Includes restructuring costs of $15.6, $10.9 and $12.2 for the years ended December 31, 2017, 2016 and 2015, respectively.


⁽²⁾	Includes acquisition-related expenses of $10.1 for the year ended December 31, 2017.

⁽³⁾


⁽⁴⁾	Includes asset impairment charges of $255.1 for the year ended December 31, 2015, attributed to E&C – $68.8, D&S – $2.0, and BioMedical – $184.3.

Product Sales Information



	Year Ended December 31,
	2017		2016		2015
Energy & Chemicals
Natural gas processing (including petrochemical) applications	$	152.9	$	105.4	$	180.9
Liquefied natural gas applications	29.5		38.2		136.1
Industrial gas applications	22.4		10.7		14.0
HVAC, power and refining	20.8		—		—
Total Energy & Chemicals	225.6		154.3		331.0
Distribution & Storage
Bulk industrial gas applications	221.9		227.6		203.9
Packaged gas industrial applications	180.7		159.7		167.8
Liquefied natural gas applications	137.7		109.8		115.9
Total Distribution & Storage	540.3		497.1		487.6
BioMedical
Respiratory therapy	124.4		118.9		132.3
Cryobiological storage	77.0		70.6		64.6
On-site generation systems	21.5		18.3		24.7
Total BioMedical	222.9		207.8		221.6
Total	$	988.8	$	859.2	$	1,040.2

Geographic Information

Net sales by geographic area are reported by the destination of sales. Net property, plant and equipment by geographic area are reported by country of domicile.



	Sales for the Year Ended December 31,
	2017		2016		2015
United States	$	526.7	$	426.0	$	513.7
Foreign
China	110.0		147.7		110.0
Other foreign countries	352.1		285.5		416.5
Total Foreign	462.1		433.2		526.5
Total	$	988.8	$	859.2	$	1,040.2



	Property, plant and equipment, net as of December 31,
	2017		2016
United States	$	177.9	$	145.0
Foreign
China	82.9		75.4
Czech Republic	20.7		18.5
Germany	13.4		11.5
Other foreign countries	2.7		0.6
Total Foreign	119.7		106.0
Total	$	297.6	$	251.0

XML 49 R27.htm IDEA: XBRL DOCUMENT

Quarterly Data (unaudited)

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information

Quarterly Data (Unaudited)

Selected quarterly data for the years ended December 31, 2017 and 2016 are as follows:



	Year Ended December 31, 2017
	First Quarter			Second Quarter		Third Quarter		Fourth Quarter		Total
Sales⁽¹⁾	$	204.1		$	238.2	$	240.5	$	306.0	$	988.8
Gross profit	55.6			63.2		70.4		82.9		272.1
Operating income ^{(1) (2)}	0.3			9.9		10.5		21.3		42.0
Net (loss) income ^{(3) (4)}	(2.9		)	3.3		2.1		27.0		29.5
Net (loss) income attributable to Chart Industries, Inc. ^{(3) (4)}	(2.9		)	2.8		1.5		26.7		28.0
Net (loss) income attributable to Chart Industries, Inc. per share—basic ⁽⁵⁾	$	(0.09	)	$	0.09	$	0.05	$	0.87	$	0.91
Net (loss) income attributable to Chart Industries, Inc. per share—diluted ^{(5) (6)}	$	(0.09	)	$	0.09	$	0.05	$	0.85	$	0.89


⁽¹⁾	Hudson, included in these results since the acquisition date, September 20, 2017, added net sales and operating income of $58.0 and $6.4 for the year ended December 31, 2017, including $6.1 and $1.2 in the third quarter and $51.9 and $5.2 in the fourth quarter, respectively.


⁽²⁾	The fourth quarter of 2017 includes additional expense as a result of a litigation award in China. Refer to Note 18, Commitments and Contingencies, for further information.


⁽³⁾	During the fourth quarter of 2017, we recorded a $4.9 loss on extinguishment of debt associated with the repurchase of $192.9 principal amount of our $250.0 2.00% convertible notes due August 2018 and refinance of our senior secured revolving credit facility.

⁽⁴⁾


⁽⁵⁾	Basic and diluted (loss) earnings per share are computed independently for each of the quarters presented. As such, the sum of quarterly basic and diluted (loss) earnings per share may not equal reported annual basic and diluted (loss) earnings per share.


⁽⁶⁾	Zero incremental shares from share-based awards are included in the computation of diluted net loss per share for periods in which a net loss occurs, because to do so would be anti-dilutive.



	Year Ended December 31, 2016
	First Quarter			Second Quarter		Third Quarter		Fourth Quarter			Total
Sales	$	193.8		$	247.1	$	203.9	$	214.4		$	859.2
Gross profit	52.7			87.0		69.6		57.1			266.4
Operating income ⁽¹⁾	0.1			34.9		20.1		2.3			57.4
Net (loss) income	(4.7		)	19.6		13.7		(3.9		)	24.7
Net (loss) income attributable to Chart Industries, Inc.	(4.7		)	21.2		15.0		(3.3		)	28.2
Net (loss) income attributable to Chart Industries, Inc. per share—basic ⁽²⁾	$	(0.15	)	$	0.69	$	0.49	$	(0.11	)	$	0.92
Net (loss) income attributable to Chart Industries, Inc. per share—diluted ^{(2) (3)}	$	(0.15	)	$	0.68	$	0.48	$	(0.11	)	$	0.91

During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes impairment of goodwill and intangible assets totaling $1.2 as described in Note 3, Asset Impairments, to the consolidated financial statements.

⁽¹⁾


⁽²⁾	Basic and diluted (loss) earnings per share are computed independently for each of the quarters presented. As such, the sum of quarterly basic and diluted (loss) earnings per share may not equal reported annual basic and diluted (loss) earnings per share.


⁽³⁾	Zero incremental shares from share-based awards are included in the computation of diluted net loss per share for periods in which a net loss occurs, because to do so would be anti-dilutive.

XML 50 R28.htm IDEA: XBRL DOCUMENT

Subsequent Events (Notes)	12 Months Ended
Subsequent Events (Notes)	Dec. 31, 2017
Subsequent Event [Line Items]
Subsequent Events [Text Block]	Subsequent Event We acquired 100% of the equity interests of Skaff Cryogenics and Cryo-Lease, LLC (together “Skaff”) on January 2, 2018 for an approximate purchase price of $12.5. Skaff provides quality repair service and remanufacturing of cryogenic and liquefied natural gas storage tanks and trailers and also maintains a portfolio of cryogenic storage equipment that is leased to customers for temporary and permanent needs. Skaff is headquartered in Brentwood, New Hampshire and provides services and equipment to customers in North America. Skaff’s results will be included in the D&S operating segment.

XML 51 R29.htm IDEA: XBRL DOCUMENT

Schedule II - Valuation and Qualifying Accounts

Valuation and Qualifying Accounts [Abstract]

Schedule of Valuation and Qualifying Accounts Disclosure

CHART INDUSTRIES, INC. AND SUBSIDIARIES

SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS

(Dollars in millions)



			Additions
	Balance at beginning of period		Charged to costs and expenses		Deductions				Translations			Balance at end of period
Year Ended December 31, 2017:
Allowance for doubtful accounts	$	10.2	$	1.2	$	(1.2	)	⁽¹⁾	$	0.6		$	10.8
Allowance for obsolete and excess inventory	10.1		2.4		(4.9		)	⁽²⁾	0.9			8.5
Deferred tax assets valuation allowance	15.1		11.1		—			⁽³⁾	1.0			27.2
Year Ended December 31, 2016:
Allowance for doubtful accounts	$	7.0	$	4.7	$	(1.3	)	⁽¹⁾	$	(0.2	)	$	10.2
Allowance for obsolete and excess inventory	11.3		3.8		(4.7		)	⁽²⁾	(0.3		)	10.1
Deferred tax assets valuation allowance	8.8		7.0		(0.1		)	⁽³⁾	(0.6		)	15.1
Year Ended December 31, 2015:
Allowance for doubtful accounts	$	6.5	$	1.6	$	(0.9	)	⁽¹⁾	$	(0.2	)	$	7.0
Allowance for obsolete and excess inventory	5.2		14.8		(8.3		)	⁽²⁾	(0.4		)	11.3
Deferred tax assets valuation allowance	1.9		7.2		(0.1		)	⁽³⁾	(0.2		)	8.8

XML 52 R30.htm IDEA: XBRL DOCUMENT


⁽¹⁾	Reversal of amounts previously recorded as bad debt and uncollectible accounts written off.


⁽²⁾	Inventory items written off against the allowance.


⁽³⁾	Deductions to the deferred tax assets valuation allowance relate to decreased deferred tax assets and the release of the valuation allowance.

Nature of Operations and Principles of Consolidation Principals of Consolidation (Policies)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation: The consolidated financial statements include the accounts of Chart Industries, Inc. and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.

XML 53 R31.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Use of Estimates, Policy [Policy Text Block]

Cash and Cash Equivalents

Accounts Receivable, Net of Allowances

Inventories

Property, Plant and Equipment

Guarantees [Text Block]

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

See Note 3, Asset Impairments, for more information relating to finite-lived intangible asset impairment losses recorded during 2016 and 2015.

Goodwill and Intangible Assets

With respect to indefinite-lived intangible assets, we first evaluate relevant events and circumstances to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount. If, in weighing all relevant events and circumstances in totality, we determine that it is more likely than not that an indefinite-lived intangible asset is not impaired, no further action is necessary. Otherwise, we would determine the fair value of indefinite-lived intangible assets and perform a quantitative impairment assessment by comparing the indefinite-lived intangible asset’s fair value to its carrying amount. We may bypass such a qualitative assessment and proceed directly to the quantitative assessment. We estimate the fair value of the indefinite-lived assets using the income approach. This may include the relief from royalty method or use of a model similar to the one described above related to goodwill which estimates the future cash flows attributed to the indefinite-lived intangible asset and then discounting these cash flows back to a present value. Under the relief from royalty method, fair value is estimated by discounting the royalty savings, as well as any tax benefits related to ownership to a present value. The fair value from either approach is compared to the carrying value and an impairment is recorded if the fair value is determined to be less than the carrying value.

Convertible Debt [Policy Text Block]

Fair Value of Financial Instruments, Policy

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Derivative Instruments

Product Warranties

We expense acquisition-related costs, including legal, consulting, accounting and other costs, in the periods in which the costs are incurred.

Revenue Recognition

We report sales net of tax assessed by governmental authorities.

Cost of Sales

Selling, General and Administrative Costs (SG&A)

Shipping and Handling Costs

Advertising Costs

Research and Development Costs

Foreign Currency Translation

Income Taxes

Interest and penalties related to income taxes are accounted for as income tax expense on the consolidated statements of operations.

We have accounted for the tax effects of the Tax Cuts and Jobs Act, which was signed into law on December 22, 2017, on a provisional basis. Our accounting for certain income tax effects is incomplete, but we have determined reasonable estimates for those effects and have recorded provisional amounts in our financial statements as of December 31, 2017. As we complete our analysis of the Tax Cuts and Jobs Act, further collect and analyze data, interpret any additional guidance issued by the U.S. Treasury Department, the Internal Revenue Service (“IRS”), and other standard-setting bodies, we may make adjustments to the provisional amounts. Those adjustments may materially impact our provision for income taxes in the period in which the adjustments are made.

Share-based Compensation

Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]

New Accounting Pronouncement, Policy [Policy Text Block]


•	Certain operations that have historically recognized revenue at a point-in-time will be required to change to the over time revenue recognition model as certain contracts contain language that meets the over time criteria established in ASC 606.


•	A portion of the revenue that has been deferred due to the current guidance for bill and hold revenues will be required to be recognized when the manufacturing process has been completed.

We do not expect the above changes to be material to our consolidated financial statements. We expect adoption to increase the level of disclosures related to revenue recognition.

XML 54 R32.htm IDEA: XBRL DOCUMENT

Asset Impairments (Tables)

Asset Impairment Charges [Table Text Block]

Asset Impairment Charges [Abstract]



	December 31, 2016
	Goodwill and Indefinite-lived Intangible Assets		Finite-lived Intangible Assets		Property, Plant & Equipment		Total
Distribution & Storage	—		$	0.5	$	0.7	$	1.2
Consolidated	$	—	$	0.5	$	0.7	$	1.2



	December 31, 2015
	Goodwill and Indefinite-lived Intangible Assets		Finite-lived Intangible Assets		Property, Plant & Equipment		Total
Energy & Chemicals	$	65.0	$	—	$	3.8	$	68.8
Distribution & Storage ⁽¹⁾	0.3		—		1.7		2.0
BioMedical	142.3		38.1		3.9		184.3
Consolidated	$	207.6	$	38.1	$	9.4	$	255.1

XML 55 R33.htm IDEA: XBRL DOCUMENT


⁽¹⁾	Asset impairments of $1.5 were included in cost of sales on the consolidated statement of operations for the year ended December 31, 2015.

Inventories (Tables)

Schedule of Inventory, Current

Inventory Disclosure [Abstract]

The following table summarizes the components of inventory:



	December 31,
	2017		2016
Raw materials and supplies	$	97.2	$	65.7
Work in process	37.4		31.6
Finished goods	74.3		72.4
Total inventories, net	$	208.9	$	169.7

XML 56 R34.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment (Tables)

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

The following table summarizes the components of property, plant and equipment:



		December 31,
Classification	Estimated Useful Life	2017			2016
Land and buildings	20-35 years	$	231.4		$	163.0
Machinery and equipment	3-12 years	199.7			169.4
Computer equipment, furniture and fixtures	3-7 years	37.0			35.4
Construction in process		26.6			50.9
Total property, plant and equipment, gross		494.7			418.7
Less: accumulated depreciation		(197.1		)	(167.7		)
Total property, plant and equipment, net		$	297.6		$	251.0

XML 57 R35.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets (Tables)

Schedule of Goodwill [Table Text Block]

Goodwill [Line Items]

The following table represents the changes in goodwill by segment:



	Energy & Chemicals		Distribution & Storage			BioMedical			Total
Balance at January 1, 2016	$	27.9	$	165.9		$	24.6		$	218.4
Foreign currency translation adjustments and other	—		(0.4		)	—			(0.4		)
Balance at December 31, 2016	27.9		165.5			24.6			218.0
Foreign currency translation adjustments and other	0.1		2.5			(0.1		)	2.5
Goodwill acquired during the year	247.1		1.2			—			248.3
Balance at December 31, 2017	$	275.1	$	169.2		$	24.5		$	468.8

Accumulated goodwill impairment loss at December 31, 2017 and 2016	$	64.6	$	—		$	131.2		$	195.8

Schedule Of Finite Lived And Indefinite Lived Intangible Assets [Table Text Block]

The following table displays the gross carrying amount and accumulated amortization for finite-lived intangible assets and indefinite-lived intangible assets (exclusive of goodwill) ⁽¹⁾:



		December 31, 2017					December 31, 2016
	Weighted-average Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization			Gross Carrying Amount		Accumulated Amortization
Finite-lived intangible assets:
Customer relationships	12 years	$	246.3	$	(88.2	)	$	119.3	$	(81.6	)
Unpatented technology	12 years	26.8		(4.5		)	8.2		(3.1		)
Land use rights	50 years	13.4		(1.2		)	12.7		(0.9		)
Trademarks and trade names	14 years	5.5		(2.9		)	4.9		(2.2		)
Patents and other	6 years	3.0		(0.8		)	1.2		(0.7		)
Total finite-lived intangible assets	14 years	$	295.0	$	(97.6	)	$	146.3	$	(88.5	)
Indefinite-lived intangible assets:
Trademarks and trade names		$	105.1				$	35.6

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]


⁽¹⁾	Amounts include the impact of foreign currency translation. Fully amortized or impaired amounts are written off.

estimate amortization expense to be recognized during the next five years as follows:



For the Year Ending December 31,
2018	$	25.8
2019	25.4
2020	23.4
2021	17.3
2022	17.1

XML 58 R36.htm IDEA: XBRL DOCUMENT

Debt And Credit Arrangements Tables (Tables)

Schedule of Debt [Table Text Block]

The following table represents the components of our borrowings:



	December 31,
	2017			2016
Convertible notes due November 2024:
Principal amount	$	258.8		$	—
Unamortized discount	(57.6		)	—
Unamortized debt issuance costs	(5.1		)	—
Convertible notes due November 2024, net of unamortized discount and debt issuance costs	196.1			—

Convertible notes due August 2018:
Principal amount	57.1			250.0
Unamortized discount	(1.9		)	(21.9		)
Unamortized debt issuance costs	(0.1		)	(1.1		)
Convertible notes due August 2018, net of unamortized discount and debt issuance costs	55.1			227.0

Senior secured revolving credit facility due November 2022	239.0			—
Foreign facilities	7.9			13.2
Total debt, net of unamortized discount and debt issuance costs	498.1			240.2
Less: current maturities ⁽¹⁾	(58.9		)	(6.5		)
Long-term debt	$	439.2		$	233.7

Schedule of Maturities of Long-term Debt [Table Text Block]


⁽¹⁾	Current maturities at December 31, 2017 includes $55.1 of Convertible notes due August 2018, net of unamortized discount and debt issuance costs.

annual maturities of debt at December 31, 2017, are as follows:



Year	Amount
2018 ⁽¹⁾	$	60.9
2019	4.1
2022	239.0
Thereafter	258.8
Total	$	562.8

Convertible Notes, due 2024 [Member]


⁽¹⁾	Includes the $57.1 fully accreted amount of our 2018 Notes and $3.8 current maturities related to foreign facilities.

Cash paid for

Schedule of Interest Accretion, Loss on Extinguishment, and Amortization of Financing Costs [Table Text Block]

The following table summarizes interest accretion of the 2024 Notes discount, 1.0% contractual interest coupon and financing costs amortization associated with the 2024 Notes:



	Year Ended December 31, 2017
2024 Notes, interest accretion of convertible notes discount	$	1.1
2024 Notes, 1.0% contractual interest coupon	0.4
2024 Notes, total interest expense	$	1.5

2024 Notes, financing costs amortization	$	0.1

Convertible Notes, Due 2018 [Member]

Schedule of Interest Accretion, Loss on Extinguishment, and Amortization of Financing Costs [Table Text Block]



	Year Ended December 31,
	2017		2016		2015
2018 Notes, interest accretion of convertible notes discount	$	11.8	$	12.5	$	11.5
2018 Notes, 2.0% contractual interest coupon	4.3		5.0		5.0
2018 Notes, total interest expense	$	16.1	$	17.5	$	16.5

2018 Notes, loss on extinguishment of debt, bond cost portion	4.3		—		—
2018 Notes, write off of unamortized debt issuance costs	0.4		—		—
2018 Notes, total loss on extinguishment of debt ⁽¹⁾	$	4.7	$	—	$	—

2018 Notes, financing costs amortization	$	0.6	$	0.7	$	0.7

XML 59 R37.htm IDEA: XBRL DOCUMENT

Product Warranties (Tables)

Product Warranties Disclosures [Abstract]

Schedule of Product Warranty Liability [Table Text Block]

The following table represents changes in our consolidated warranty reserve:



	Year Ended December 31,
	2017			2016			2015
Beginning Balance	$	18.3		$	21.0		$	24.2
Issued - Warranty Expense	7.1			8.8			13.7
Acquired - Warranty Reserve	0.9			—			—
Change in Estimate - Warranty Expense	2.1			1.2			3.0
Warranty Usage	(11.7		)	(12.7		)	(19.9		)
Ending Balance	$	16.7		$	18.3		$	21.0

XML 60 R38.htm IDEA: XBRL DOCUMENT

Business Combinations (Tables)

Business Acquisition, Contingent Consideration [Line Items]

Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

Information regarding identifiable intangible assets acquired in the Hudson acquisition is presented below:



	Weighted-average Estimated Useful Life	Preliminary Estimated Asset Fair Value
Finite-lived intangible assets:
Customer relationships	13 years	$	122.1
Unpatented technology	10 years	18.3
Customer backlog ⁽¹⁾	2 years	1.3
Total finite-lived intangible assets acquired	12 years	141.7
Indefinite-lived intangible assets:
Trademarks and trade names		69.3
Total identifiable intangible assets acquired		$	211.0

Business Acquisition, Pro Forma Information [Table Text Block]


⁽¹⁾	Customer backlog acquired is included in “Patents and other” in Note 6. Goodwill and Intangible Assets.



	Year Ended December 31,
	2017		2016
Pro forma sales	$	1,130.0	$	1,029.0
Pro forma net income attributable to Chart Industries, Inc.	16.8		17.1

Pro forma net income attributable to Chart Industries, Inc. per common share, basic	0.55		0.56
Pro forma net income attributable to Chart Industries, Inc. per common share, diluted	0.54		0.55

Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]

The following table represents the changes in contingent consideration liabilities by segment:



	Distribution & Storage			BioMedical			Total
Balance at January 1, 2015	$	—		$	1.1		$	1.1
Fair value of contingent consideration at inception	1.8			—			1.8
Decrease in fair value of contingent consideration liabilities	—			(0.5		)	(0.5		)
Payment of contingent consideration	—			(0.6		)	(0.6		)
Balance at December 31, 2015	1.8			—			1.8
Increase in fair value of contingent consideration liabilities	0.1			—			0.1
Balance at December 31, 2016	1.9			—			1.9
Decrease in fair value of contingent consideration liabilities	(1.6		)	—			(1.6		)
Balance at December 31, 2017	$	0.3		$	—		$	0.3

Business Acquisition, Contingent Consideration [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed in the Hudson acquisition:



	December 31, 2017			Adjustments			As Previously Reported September 30, 2017
Net assets acquired:
Goodwill	$	238.3		$	10.9		$	227.4
Identifiable intangible assets	211.0			9.0			202.0
Accounts receivable	34.6			—			34.6
Property, plant and equipment	29.4			(1.2		)	30.6
Inventories	26.5			1.6			24.9
Other current assets ⁽¹⁾	8.1			(1.2		)	9.3
Unbilled contract revenue	4.9			0.3			4.6
Other assets	2.9			—			2.9
Prepaid expenses	0.9			—			0.9
Deferred tax liabilities	(87.6		)	(19.0		)	(68.6		)
Accounts payable	(21.2		)	—			(21.2		)
Customer advances and billings in excess of contract revenue	(17.4		)	(0.5		)	(16.9		)
Accrued salaries, wages and benefits	(4.4		)	—			(4.4		)
Other current liabilities	(3.8		)	0.2			(4.0		)
Other long-term liabilities	(1.9		)	—			(1.9		)
Current portion of warranty reserve	(0.8		)	—			(0.8		)
Net assets acquired	$	419.5		$	0.1		$	419.4

Business Acquisition, Contingent Consideration [Line Items]


⁽¹⁾	Pursuant to the provisions of the Merger Agreement, Hudson deposited $2.3 into a Rabbi Trust which represents amounts payable to eligible parties under Long-Term Incentive Agreements. This balance is treated as restricted cash and restricted cash equivalents in the consolidated balance sheets and is classified as other current assets.

Hetsco [Member]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]



	December 31, 2017		Adjustments			As Previously Reported March 31, 2017
Goodwill	$	8.8	$	(1.3	)	$	10.1
Identifiable intangible assets – customer relationships	8.1		0.8			7.3
Other identifiable intangible assets	1.2		—			1.2
Other net assets	4.7		0.1			4.6
Net assets acquired	$	22.8	$	(0.4	)	$	23.2

XML 61 R39.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

Financial assets and liabilities measured at fair value on a recurring basis and presented in our consolidated balance sheets are as follows:



	December 31, 2017
	Total		Level 2		Level 3
Foreign currency forward contracts	$	0.1	$	0.1	$	—
Total financial assets	$	0.1	$	0.1	$	—

Contingent consideration liabilities	$	0.3	$	—	$	0.3
Total financial liabilities	$	0.3	$	—	$	0.3



	December 31, 2016
	Total		Level 2		Level 3
Foreign currency forward contracts	$	0.1	$	0.1	$	—
Contingent consideration liabilities	1.9		—		1.9
Total financial liabilities	$	2.0	$	0.1	$	1.9

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 62 R40.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss (Tables)

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Equity [Abstract]



	December 31, 2017
	Foreign currency translation adjustments			Pension liability adjustments, net of taxes			Accumulated other comprehensive loss
Beginning Balance	$	(24.7	)	$	(10.5	)	$	(35.2	)
Other comprehensive income before reclassifications, net of a tax expense of $2.9	25.6			(0.5		)	25.0
Amounts reclassified from accumulated other comprehensive loss, net of taxes of $0.4 ^{(1) (2)}	1.3			0.8			2.1
Net current-period other comprehensive income, net of taxes	26.9			0.3			27.1
Ending Balance	$	2.2		$	(10.2	)	$	(8.1	)



	December 31, 2016
	Foreign currency translation adjustments			Pension liability adjustments, net of taxes			Accumulated other comprehensive loss
Beginning Balance	$	(12.5	)	$	(12.4	)	$	(24.9	)
Other comprehensive (loss) income before reclassifications, net of taxes of $0.6	(12.2		)	0.9			(11.3		)
Amounts reclassified from accumulated other comprehensive loss, net of taxes of $0.5 ⁽¹⁾	—			1.0			1.0
Net current-period other comprehensive (loss) income, net of taxes	(12.2		)	1.9			(10.3		)
Ending Balance	$	(24.7	)	$	(10.5	)	$	(35.2	)

XML 63 R41.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Tables)

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

Earnings Per Share [Abstract]

The following table presents calculations of net income (loss) per share of common stock:



	Year Ended December 31,
	2017		2016		2015
Net income (loss) attributable to Chart Industries, Inc.	$	28.0	$	28.2	$	(203.0	)
Net income (loss) attributable to Chart Industries, Inc. per common share:
Basic	$	0.91	$	0.92	$	(6.66	)
Diluted	$	0.89	$	0.91	$	(6.66	)

Weighted average number of common shares outstanding — basic	30.74		30.58		30.49
Incremental shares issuable upon assumed conversion and exercise of share-based awards	0.60		0.41		—
Weighted average number of common shares outstanding — diluted	31.34		30.99		30.49

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

Diluted earnings per share does not consider the following potential common shares as the effect would be anti-dilutive:



	Year Ended December 31,
	2017	2016	2015
Share-based awards	0.40	0.56	0.94
Warrants	5.18	3.37	3.37
Total anti-dilutive securities	5.58	3.93	4.31

XML 64 R42.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

Schedule of Income before Income Tax, Domestic and Foreign

Income Tax Disclosure [Abstract]

Income (loss) before income taxes consists of the following:



	Year Ended December 31,
	2017		2016			2015
United States	$	2.7	$	40.5		$	(187.2	)
Foreign	10.9		(2.1		)	(14.6		)
Income (loss) before income taxes	$	13.6	$	38.4		$	(201.8	)

Schedule of Components of Income Tax Expense (Benefit)

Significant components of income tax (benefit) expense are as follows:



	Year Ended December 31,
	2017			2016			2015
Current:
Federal	$	6.1		$	10.0		$	22.9
State and local	0.5			1.0			1.1
Foreign	7.3			5.3			3.1
Total current	13.9			16.3			27.1
Deferred:
Federal	(28.8		)	(3.3		)	(25.7		)
State and local	(0.4		)	(0.2		)	(0.6		)
Foreign	(0.6		)	0.9			1.9
Total deferred	(29.8		)	(2.6		)	(24.4		)
Total income tax (benefit) expense	$	(15.9	)	$	13.7		$	2.7

Schedule of Effective Income Tax Rate Reconciliation

The reconciliation of income taxes computed at the U.S. federal statutory tax rate to income tax (benefit) expense is as follows:



	Year Ended December 31,
	2017			2016			2015
Income tax expense (benefit) at U.S. statutory rate	$	4.8		$	13.4		$	(70.6	)
State income taxes, net of federal tax benefit	0.6			0.7			0.4
Foreign income, net of credit on foreign taxes	8.8			0.2			—
Effective tax rate differential of earnings outside of U.S.	(0.5		)	0.5			—
Change in valuation allowance	7.8			6.6			5.6
Research & experimentation credits	(0.6		)	(0.9		)	(0.9		)
Non-deductible items	0.6			0.7			2.7
Change in uncertain tax positions	0.1			(0.2		)	0.1
Domestic production activities deduction	(0.4		)	(1.2		)	(2.1		)
Tax effect of asset impairments	—			—			67.3
Tax effect of insurance proceeds	—			(5.8		)	—
Tax effect of 2017 tax reform federal rate change	(26.9		)	—			—
Tax effect of carryforward foreign tax credits	(10.3		)	—			—
Other items	0.1			(0.3		)	0.2
Income tax (benefit) expense	$	(15.9	)	$	13.7		$	2.7

Schedule of Deferred Tax Assets and Liabilities

Significant components of our deferred tax assets and liabilities are as follows:



	December 31,
	2017			2016
Deferred tax assets:
Accruals and reserves	$	11.8		$	24.1
Pensions	2.0			5.3
Inventory	4.3			6.8
Share-based compensation	6.6			9.4
Tax credit carryforwards	16.4			2.2
Foreign net operating loss carryforwards	12.4			5.9
State net operating loss carryforwards	2.0			1.6
Other – net	0.2			0.9
Total deferred tax assets before valuation allowances	55.7			56.2
Valuation allowances	(27.2		)	(15.1		)
Total deferred tax assets, net of valuation allowances	$	28.5		$	41.1
Deferred tax liabilities:
Property, plant and equipment	$	15.0		$	19.4
Goodwill and intangible assets	72.9			22.9
Convertible notes	(0.5		)	1.0
Other – net	2.9			—
Total deferred tax liabilities	$	90.3		$	43.3
Net deferred tax liabilities	$	61.8		$	2.2
The net deferred tax liability is classified as follows:
Other assets	(0.7		)	(2.0		)
Long-term deferred tax liabilities	62.5			4.2
Net deferred tax liabilities	$	61.8		$	2.2

Summary of Income Tax Contingencies [Table Text Block]

The reconciliation of beginning to ending unrecognized tax benefits is as follows:



	Year Ended December 31,
	2017			2016			2015
Unrecognized tax benefits at beginning of the year	$	0.8		$	1.0		$	0.9
Additions for tax positions of prior years	0.1			—			0.1
Reductions for tax positions of prior years	(0.1		)	—			—
Lapse of statutes of limitation	—			(0.2		)	—
Unrecognized tax benefits at end of the year	$	0.8		$	0.8		$	1.0

XML 65 R43.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans (Tables)

Schedule of Net Benefit Costs

Retirement Benefits [Abstract]

The components of net periodic pension expense are as follows:



	Year Ended December 31,
	2017			2016			2015
Interest cost	$	2.2		$	2.3		$	2.3
Expected return on plan assets	(2.8		)	(2.8		)	(3.2		)
Amortization of net loss	1.2			1.5			1.4
Total net periodic pension expense	$	0.6		$	1.0		$	0.5

Schedule of Changes in Projected Benefit Obligation and Plan Assets, Funded Status and Amounts Recognized on the Balance Sheet

The changes in the projected benefit obligation and plan assets, the funded status of the plans and the amounts recognized in the consolidated balance sheets are as follows:



	December 31,
	2017			2016
Change in projected benefit obligation:
Projected benefit obligation at beginning of year	$	55.5		$	58.3
Interest cost	2.2			2.3
Benefits paid	(2.3		)	(3.9		)
Actuarial gains (losses)	1.6			(1.2		)
Projected benefit obligation at year end	$	57.0		$	55.5
Change in plan assets:
Fair value of plan assets at beginning of year	$	41.1		$	41.0
Actual return	6.7			3.0
Employer contributions	3.0			1.0
Benefits paid	(2.3		)	(3.9		)
Fair value of plan assets at year end	$	48.5		$	41.1
Funded status (Accrued pension liabilities) ⁽¹⁾	$	(8.5	)	$	(14.4	)

Unrecognized actuarial loss recognized in accumulated other comprehensive loss	$	13.2		$	16.7

Schedule of Assumptions Used

The actuarial assumptions used in determining pension plan information are as follows:



	December 31,
	2017		2016		2015
Assumptions used to determine benefit obligation at year end:
Discount rate	3.7	%	4.0	%	4.0	%
Assumptions used to determine net periodic benefit cost:
Discount rate	4.0	%	4.0	%	3.8	%
Expected long-term weighted-average rate of return on plan assets	7.0	%	7.0	%	7.3	%

Schedule of Allocation of Plan Assets [Table Text Block]

The target allocations by asset category and fair values of the plan assets by asset class at December 31 are as follows:



	Target Allocations by Asset Category	Fair Value
		Total				Level 2				Level 3
Plan Assets:		2017		2016		2017		2016		2017		2016
Equity funds	60% – 68%	$	33.0	$	28.1	$	33.0	$	28.1	$	—	$	—
Fixed income funds	26% – 30%	12.6		11.7		12.6		11.7		—		—
Other investments	3% – 6%	2.9		1.3		—		—		2.9		1.3
Total		$	48.5	$	41.1	$	45.6	$	39.8	$	2.9	$	1.3

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table represents changes in the fair value of plan assets categorized as Level 3 from the preceding table:



Balance at January 1, 2016	$	0.3
Purchases, sales and settlements, net	(4.2		)
Transfers, net	5.2
Balance at December 31, 2016	$	1.3
Purchases, sales and settlements, net	(2.4		)
Transfers, net	4.0
Balance at December 31, 2017	$	2.9

Schedule of Expected Benefit Payments

The following benefit payments are expected to be paid by the plan in each of the next five years and in the aggregate for the subsequent five years:



2018	$	2.6
2019	2.8
2020	2.9
2021	3.0
2022	3.1
In aggregate during five years thereafter	16.6

XML 66 R44.htm IDEA: XBRL DOCUMENT

Share-based Compensation (Tables)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Weighted-average grant-date fair values of stock options and the assumptions used in estimating the fair values are as follows:



	Year Ended December 31,
	2017			2016			2015
Weighted-average grant-date fair value per share	$	20.10		$	10.36		$	19.04
Expected term (years)	5.4			5.2			5.6
Risk-free interest rate	2.00		%	1.66		%	1.70		%
Expected volatility	60.31		%	61.40		%	61.54		%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

The following table summarizes our stock option activity:



	December 31, 2017
	Number of Shares		Weighted-average Exercise Price		Aggregate Intrinsic Value		Weighted- average Remaining Contractual Term
Outstanding at beginning of year	1.11		$	31.13
Granted	0.32		37.06
Exercised	(0.08	)	25.71
Forfeited / Cancelled	(0.10	)	36.16
Outstanding at end of year	1.25		$	32.58	$	21.9	6.4 years
Vested and expected to vest at end of year	1.24		$	32.60	$	9.4	6.4 years
Exercisable at end of year	0.56		$	36.29	$	21.7	4.7 years

Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]

The following table summarizes our unvested restricted stock and RSUs activity:



	December 31, 2017
	Number of Shares		Weighted-Average Grant-Date Fair Value
Unvested at beginning of year	0.33		$	24.06
Granted	0.16		37.13
Forfeited	(0.03	)	26.51
Vested	(0.13	)	28.52
Unvested at end of year	0.33		$	28.38

Performance units [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation, Activity [Table Text Block]

The following table, which is stated at a 100% earned percentage, summarizes our performance units activity:



	December 31, 2017
	Number of Shares		Weighted-Average Grant-Date Fair Value
Unvested at beginning of year	0.08		$	31.84
Granted	0.03		38.00
Forfeited / Cancelled	(0.01	)	31.14
Vested	(0.02	)	93.34
Unvested at end of year	0.08		$	24.81

Leveraged Restricted Share Awards [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation, Activity [Table Text Block]

The following table, which is stated at a 100% earned percentage, summarizes our leveraged restricted share unit awards activity:



	December 31, 2017
	Number of Shares		Weighted-average Grant-Date Fair Value
Unvested at beginning of year	0.010		$	106.90
Forfeited / Cancelled	(0.005	)	106.90
Vested	(0.005	)	106.90
Unvested at end of year	—		$	—

XML 67 R45.htm IDEA: XBRL DOCUMENT

Lease Commitments (Tables)

Operating Leases of Lessee Disclosure

Leases [Abstract]

The following table summarizes future minimum lease payments for non-cancelable operating leases as of December 31, 2017:



2018	$	9.2
2019	7.1
2020	5.6
2021	4.1
2022	3.8
Thereafter	10.8
Total future minimum lease payments	$	40.6

XML 68 R46.htm IDEA: XBRL DOCUMENT

Restructuring Activities (Tables)

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs [Table Text Block]



	Year Ended December 31,
	2017		2016		2015
Severance:
Cost of sales	$	0.8	$	4.2	$	2.2
Selling, general, and administrative expenses	3.8		5.8		5.2
Total severance costs	$	4.6	$	10.0	$	7.4
Other restructuring:
Cost of sales	$	4.4	$	0.2	$	1.4
Selling, general, and administrative expenses	6.6		0.7		3.4
Total other restructuring costs	$	11.0	$	0.9	$	4.8

Total restructuring costs	$	15.6	$	10.9	$	12.2

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

The following tables summarize our restructuring activities for the years ended 2017, 2016 and 2015:



	Twelve Months Ended December 31, 2017
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of December 31, 2016	$	0.1		$	2.9		$	1.3		$	3.0		$	7.3
Restructuring costs	2.4			2.2			5.0			6.0			15.6
Cash payments	(2.5		)	(3.9		)	(6.0		)	(7.9		)	(20.3		)
Acquired restructuring reserve	0.2			—			—			—			0.2
Balance as of December 31, 2017	$	0.2		$	1.2		$	0.3		$	1.1		$	2.8



	Twelve Months Ended December 31, 2016
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of December 31, 2015	$	1.1		$	3.4		$	0.4		$	0.9		$	5.8
Restructuring costs	1.0			3.8			1.9			4.2			10.9
Cash payments	(2.0		)	(4.3		)	(1.0		)	(2.1		)	(9.4		)
Balance as of December 31, 2016	$	0.1		$	2.9		$	1.3		$	3.0		$	7.3



	Twelve Months Ended December 31, 2015
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of December 31, 2014	$	—		$	—		$	—		$	—		$	—
Restructuring costs	1.4			7.7			1.8			1.3			12.2
Cash payments	(0.3		)	(4.3		)	(1.4		)	(0.4		)	(6.4		)
Balance as of December 31, 2015	$	1.1		$	3.4		$	0.4		$	0.9		$	5.8

XML 69 R47.htm IDEA: XBRL DOCUMENT

Segment and Geographic Information (Tables)

Schedule of Segment Reporting Information, by Segment

Segment Reporting [Abstract]



	Year Ended December 31, 2017
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales to external customers	$	225.6	$	540.3	$	222.9	$	—		$	988.8
Depreciation and amortization expense	15.3		18.8		5.6		2.2			41.9
Operating income (loss) ^{(1) (2)}	5.1		66.1		35.5		(64.7		)	42.0
Total assets	782.9		685.2		165.9		90.7			1,724.7
Capital expenditures	15.5		14.4		3.0		2.3			35.2



	Year Ended December 31, 2016
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales to external customers	$	154.3	$	497.1	$	207.8	$	—		$	859.2
Depreciation and amortization expense	10.0		18.4		6.0		3.1			37.5
Operating income (loss) ^{(1) (3)}	13.3		50.4		42.0		(48.3		)	57.4
Total assets	177.5		657.6		178.7		219.2			1,233.0
Capital expenditures	3.3		11.7		2.3		0.5			17.8



	Year Ended December 31, 2015
	Energy & Chemicals			Distribution & Storage		BioMedical			Corporate			Total
Sales to external customers	$	331.0		$	487.6	$	221.6		$	—		$	1,040.2
Depreciation and amortization expense	11.8			18.3		12.0			3.3			45.4
Operating (loss) income ^{(1) (4)}	(10.0		)	39.5		(165.3		)	(47.4		)	(183.2		)
Total assets	251.8			689.1		224.4			34.8			1,200.1
Capital expenditures	4.1			36.8		3.9			2.3			47.1

During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes asset impairment charges of $1.2 attributed to D&S.


⁽¹⁾	Includes restructuring costs of $15.6, $10.9 and $12.2 for the years ended December 31, 2017, 2016 and 2015, respectively.


⁽²⁾	Includes acquisition-related expenses of $10.1 for the year ended December 31, 2017.

⁽³⁾


⁽⁴⁾	Includes asset impairment charges of $255.1 for the year ended December 31, 2015, attributed to E&C – $68.8, D&S – $2.0, and BioMedical – $184.3.

Revenue from External Customers by Products and Services [Table Text Block]



	Year Ended December 31,
	2017		2016		2015
Energy & Chemicals
Natural gas processing (including petrochemical) applications	$	152.9	$	105.4	$	180.9
Liquefied natural gas applications	29.5		38.2		136.1
Industrial gas applications	22.4		10.7		14.0
HVAC, power and refining	20.8		—		—
Total Energy & Chemicals	225.6		154.3		331.0
Distribution & Storage
Bulk industrial gas applications	221.9		227.6		203.9
Packaged gas industrial applications	180.7		159.7		167.8
Liquefied natural gas applications	137.7		109.8		115.9
Total Distribution & Storage	540.3		497.1		487.6
BioMedical
Respiratory therapy	124.4		118.9		132.3
Cryobiological storage	77.0		70.6		64.6
On-site generation systems	21.5		18.3		24.7
Total BioMedical	222.9		207.8		221.6
Total	$	988.8	$	859.2	$	1,040.2

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

Net sales by geographic area are reported by the destination of sales. Net property, plant and equipment by geographic area are reported by country of domicile.



	Sales for the Year Ended December 31,
	2017		2016		2015
United States	$	526.7	$	426.0	$	513.7
Foreign
China	110.0		147.7		110.0
Other foreign countries	352.1		285.5		416.5
Total Foreign	462.1		433.2		526.5
Total	$	988.8	$	859.2	$	1,040.2



	Property, plant and equipment, net as of December 31,
	2017		2016
United States	$	177.9	$	145.0
Foreign
China	82.9		75.4
Czech Republic	20.7		18.5
Germany	13.4		11.5
Other foreign countries	2.7		0.6
Total Foreign	119.7		106.0
Total	$	297.6	$	251.0

XML 70 R48.htm IDEA: XBRL DOCUMENT

Quarterly Data (unaudited) (Tables)

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

Selected quarterly data for the years ended December 31, 2017 and 2016 are as follows:



	Year Ended December 31, 2017
	First Quarter			Second Quarter		Third Quarter		Fourth Quarter		Total
Sales⁽¹⁾	$	204.1		$	238.2	$	240.5	$	306.0	$	988.8
Gross profit	55.6			63.2		70.4		82.9		272.1
Operating income ^{(1) (2)}	0.3			9.9		10.5		21.3		42.0
Net (loss) income ^{(3) (4)}	(2.9		)	3.3		2.1		27.0		29.5
Net (loss) income attributable to Chart Industries, Inc. ^{(3) (4)}	(2.9		)	2.8		1.5		26.7		28.0
Net (loss) income attributable to Chart Industries, Inc. per share—basic ⁽⁵⁾	$	(0.09	)	$	0.09	$	0.05	$	0.87	$	0.91
Net (loss) income attributable to Chart Industries, Inc. per share—diluted ^{(5) (6)}	$	(0.09	)	$	0.09	$	0.05	$	0.85	$	0.89


⁽¹⁾	Hudson, included in these results since the acquisition date, September 20, 2017, added net sales and operating income of $58.0 and $6.4 for the year ended December 31, 2017, including $6.1 and $1.2 in the third quarter and $51.9 and $5.2 in the fourth quarter, respectively.


⁽²⁾	The fourth quarter of 2017 includes additional expense as a result of a litigation award in China. Refer to Note 18, Commitments and Contingencies, for further information.


⁽³⁾	During the fourth quarter of 2017, we recorded a $4.9 loss on extinguishment of debt associated with the repurchase of $192.9 principal amount of our $250.0 2.00% convertible notes due August 2018 and refinance of our senior secured revolving credit facility.

⁽⁴⁾


⁽⁵⁾	Basic and diluted (loss) earnings per share are computed independently for each of the quarters presented. As such, the sum of quarterly basic and diluted (loss) earnings per share may not equal reported annual basic and diluted (loss) earnings per share.


⁽⁶⁾	Zero incremental shares from share-based awards are included in the computation of diluted net loss per share for periods in which a net loss occurs, because to do so would be anti-dilutive.



	Year Ended December 31, 2016
	First Quarter			Second Quarter		Third Quarter		Fourth Quarter			Total
Sales	$	193.8		$	247.1	$	203.9	$	214.4		$	859.2
Gross profit	52.7			87.0		69.6		57.1			266.4
Operating income ⁽¹⁾	0.1			34.9		20.1		2.3			57.4
Net (loss) income	(4.7		)	19.6		13.7		(3.9		)	24.7
Net (loss) income attributable to Chart Industries, Inc.	(4.7		)	21.2		15.0		(3.3		)	28.2
Net (loss) income attributable to Chart Industries, Inc. per share—basic ⁽²⁾	$	(0.15	)	$	0.69	$	0.49	$	(0.11	)	$	0.92
Net (loss) income attributable to Chart Industries, Inc. per share—diluted ^{(2) (3)}	$	(0.15	)	$	0.68	$	0.48	$	(0.11	)	$	0.91

During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes impairment of goodwill and intangible assets totaling $1.2 as described in Note 3, Asset Impairments, to the consolidated financial statements.

⁽¹⁾


⁽²⁾	Basic and diluted (loss) earnings per share are computed independently for each of the quarters presented. As such, the sum of quarterly basic and diluted (loss) earnings per share may not equal reported annual basic and diluted (loss) earnings per share.


⁽³⁾	Zero incremental shares from share-based awards are included in the computation of diluted net loss per share for periods in which a net loss occurs, because to do so would be anti-dilutive.

XML 71 R49.htm IDEA: XBRL DOCUMENT

Nature of Operations and Principles of Consolidation Details (Details) $ in Millions	Dec. 31, 2017 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Restricted Cash and Cash Equivalents	$ 8.8

XML 72 R50.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2017 EUR (€)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Guarantor Obligations, Term	1.5
Guarantor Obligations, Maximum Exposure, Undiscounted	$ 15.4			€ 14.6
Shipping and Handling Revenue	10.2	$ 8.7	$ 11.6
Shipping, Handling and Transportation Costs	13.9	12.2	15.2
Advertising Expense	5.1	4.7	5.1
Research and Development Expense	$ 16.0	$ 18.1	$ 15.8

XML 73 R51.htm IDEA: XBRL DOCUMENT

Asset Impairments (Details) - USD ($)
$ / shares in Units, $ in Millions

$ 0.0

$ 207.6

38.1

Asset Impairments Charges and Other PP&E Impairment

0.7

9.4

Energy & Chemicals [Member]

$ 65.0

Asset Impairments Charges and Other PP&E Impairment

3.8

68.8

Distribution & Storage [Member]

0.7

1.7

Asset Impairments Charges and Other PP&E Impairment

142.3

38.1

Asset Impairments Charges and Other PP&E Impairment

3.9

184.3

Energy & Chemical and BioMedical [Member]

Customer Relationships [Member]

$ 7.7

Unpatented Technology [Member]

15.7

XML 74 R52.htm IDEA: XBRL DOCUMENT

22.4

Cost of Sales [Member]

Asset impairments

$ 1.5

[1]	Asset impairments of $1.5 were included in cost of sales on the consolidated statement of operations for the year ended December 31, 2015.

Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Inventory [Line Items]
Inventory, Raw Materials and Supplies, Gross	$ 97.2	$ 65.7
Inventory, Work in Process, Gross	37.4	31.6
Inventory, Finished Goods, Gross	74.3	72.4
Inventories, net	208.9	169.7
Inventory Valuation Reserves	8.5	$ 10.1
Hudson [Member]
Inventory [Line Items]
Inventory, Raw Materials and Supplies, Gross	21.3
Inventories, net	$ 23.1

XML 75 R53.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 494.7	$ 418.7
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(197.1)	(167.7)
Property, plant and equipment, net	297.6	251.0
Depreciation	26.9	25.6	$ 28.1
Land, Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 231.4	163.0
Land, Buildings and Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Land, Buildings and Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	35 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 199.7	169.4
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	12 years
Computer equipment, furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 37.0	35.4
Computer equipment, furniture and fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer equipment, furniture and fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 26.6	50.9
Distribution & Storage [Member]
Property, Plant and Equipment [Line Items]
Construction in Progress, Gross		$ 46.0

XML 76 R54.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Goodwill [Line Items]
Goodwill Beginning	$ 218.0	$ 218.4
Foreign currency translation adjustments and other	(2.5)	0.4
Goodwill, Acquired During Period	248.3
Goodwill Ending	468.8	218.0
Goodwill, Impaired, Accumulated Impairment Loss	195.8	195.8
Energy & Chemicals [Member]
Goodwill [Line Items]
Goodwill Beginning	27.9	27.9
Foreign currency translation adjustments and other	(0.1)	0.0
Goodwill, Acquired During Period	247.1
Goodwill Ending	275.1	27.9
Goodwill, Impaired, Accumulated Impairment Loss	64.6	64.6
Distribution & Storage [Member]
Goodwill [Line Items]
Goodwill Beginning	165.5	165.9
Foreign currency translation adjustments and other	(2.5)	0.4
Goodwill, Acquired During Period	1.2
Goodwill Ending	169.2	165.5
Goodwill, Impaired, Accumulated Impairment Loss	0.0	0.0
BioMedical [Member]
Goodwill [Line Items]
Goodwill Beginning	24.6	24.6
Foreign currency translation adjustments and other	0.1	0.0
Goodwill, Acquired During Period	0.0
Goodwill Ending	24.5	24.6
Goodwill, Impaired, Accumulated Impairment Loss	$ 131.2	$ 131.2

XML 77 R55.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets Finite-Lived Intangible Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	14 years
Finite-Lived Intangible Assets, Gross	$ 295.0	$ 146.3
Finite-Lived Intangible Assets, Accumulated Amortization	(97.6)	(88.5)
Amortization expense	15.0	11.9	$ 17.3
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	25.8
Finite-Lived Intangible Assets, Amortization Expense, Year Two	25.4
Finite-Lived Intangible Assets, Amortization Expense, Year Three	23.4
Finite-Lived Intangible Assets, Amortization Expense, Year Four	17.3
Finite-Lived Intangible Assets, Amortization Expense, Year Five	17.1
Government grants	$ 0.4	1.1	$ 8.7
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years
Finite-Lived Intangible Assets, Gross	$ 246.3	119.3
Finite-Lived Intangible Assets, Accumulated Amortization	$ (88.2)	(81.6)
Unpatented Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years
Finite-Lived Intangible Assets, Gross	$ 26.8	8.2
Finite-Lived Intangible Assets, Accumulated Amortization	$ (4.5)	(3.1)
Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	50 years
Finite-Lived Intangible Assets, Gross	$ 13.4	12.7
Finite-Lived Intangible Assets, Accumulated Amortization	$ (1.2)	(0.9)
Use Rights [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	50 years
Trademarks and Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	14 years
Finite-Lived Intangible Assets, Gross	$ 5.5	4.9
Finite-Lived Intangible Assets, Accumulated Amortization	$ (2.9)	(2.2)
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	6 years
Finite-Lived Intangible Assets, Gross	$ 3.0	1.2
Finite-Lived Intangible Assets, Accumulated Amortization	(0.8)	(0.7)
Other Noncurrent Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Government grants	8.7	8.2
Other Current Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Government grants	$ 0.5	$ 0.4

XML 78 R56.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets Indefinite-Lived Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Trademarks and Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 105.1	$ 35.6

XML 79 R57.htm IDEA: XBRL DOCUMENT

Debt And Credit Arrangements Summary of Outstanding Borrowings (Details) - USD ($)
$ in Millions

Nov. 05, 2017

Debt, Long-term and Short-term, Combined Amount, Net of Unamortized Debt Issuance Costs and Debt Discounts

$ 250.0

498.1

$ 240.2

Current Maturities Of Long Term Debt Including Short Term Debt

58.9

Long-term Debt, Excluding Current Maturities

6.5

439.2

233.7

Convertible Notes, due 2024 [Member] | Convertible Debt [Member]

258.8

Debt Instrument, Unamortized Discount

57.6

Unamortized Debt Issuance Expense

Convertible Notes, Due 2018 [Member] | Convertible Debt [Member]

Debt Instrument, Unamortized Discount

57.1

250.0

Unamortized Debt Issuance Expense

21.9

Convertible Debt, Current

55.1

Senior Secured Revolving Credit Facility, due 2022 [Member] | Revolving Credit Facility [Member]

Unamortized Debt Issuance Expense

2.4

Long-term Debt, Gross

239.0

Senior Secured Revolving Credit Facility [Member] | Revolving Credit Facility [Member]

Long-term Debt, Gross

Foreign Facilities [Member]

XML 80 R58.htm IDEA: XBRL DOCUMENT

Long-term Debt, Gross

$ 7.9

$ 13.2

[1]	(1) Current maturities at December 31, 2017 includes $55.1 of Convertible notes due August 2018, net of unamortized discount and debt issuance costs.

Debt And Credit Arrangements 2024 Notes (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Oct. 31, 2017	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Interest Paid	$ 9,300	$ 5,600	$ 5,100
Debt Instrument, Face Amount	$ 250,000
Debt Instrument, Interest Rate, Stated Percentage	2.00%
Share Price			$ 17.96		$ 34.20	$ 95.64
Amortization of Debt Discount (Premium)	$ 12,800	12,500	$ 11,500
Amortization of Debt Issuance Costs	1,279	1,284	1,290
Payments For Call Options Related to Convertible Debt	59,500	0	0
Proceeds from Issuance of Warrants	46,000	0	$ 0
Convertible Notes, due 2024 [Member] \| Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 258,800	$ 0
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Equivalent Shares Of Common Stock Per 1000 Principal Amount Of Convertible Notes	17.0285
Debt Instrument, Convertible, Conversion Price	$ 58.73
Premium Percentage On Shares Issued from Conversion of Convertible Debt	35.00%
Share Price				$ 43.50
Debt Instrument, Interest Rate, Effective Percentage	4.80%
Amortization of Debt Discount (Premium)	$ 1,100
Interest Expense, Debt, Excluding Amortization	400
Interest Expense, Debt	1,500
Amortization of Debt Issuance Costs	100
Payments For Call Options Related to Convertible Debt	$ 59,500
Number of Shares Underlying Warrants	4,400,000
Proceeds from Issuance of Warrants	$ 46,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 71.775
Net Cost of Convertible Note Hedge and Warrants	$ 13,500
Liability Component [Member] \| Convertible Notes, due 2024 [Member] \| Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	200,100
Debt Issuance Costs, Gross	5,200
Equity Component [Member] \| Convertible Notes, due 2024 [Member] \| Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	58,700
Debt Issuance Costs, Gross	$ 1,500

XML 81 R59.htm IDEA: XBRL DOCUMENT

Debt And Credit Arrangements 2018 Notes (Details)
$ / shares in Units, $ in Thousands

Debt Instrument, Interest Rate, Stated Percentage

$ 250,000

2.00%

Debt Instrument, Repurchase Amount

$ 192,900

Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months

60,900

Interest accretion of convertible notes discount

12,800

12,500

11,500

Amortization of Debt Issuance Costs

1,279

1,284

1,290

Convertible Notes, Due 2018 [Member]

Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months

57,100

Convertible Notes, Due 2018 [Member] | Convertible Debt [Member]

Debt Instrument, Interest Rate, Stated Percentage

$ 57,100

250,000

2.00%

Debt Instrument, Interest Rate, Effective Percentage

7.90%

Repayments of Debt

$ 195,900

Debt Instrument, Repurchase Amount

$ 192,900

192,900

Interest on Convertible Debt, Net of Tax

1,000

Extinguishment of Debt, Amount

194,900

Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months

57,100

Convertible Debt, Current

$ 55,100

Fair Value Inputs, Discount Rate

Equivalent Shares Of Common Stock Per 1000 Principal Amount Of Convertible Notes | shares

$ 4,700

^[2]

Interest Paid

$ 1,000

14.4865

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 69.03

Debt Instrument, Convertible, Threshold Consecutive Trading Days

Debt Instrument, Convertible, Threshold Trading Days

Interest accretion of convertible notes discount

$ 11,800

12,500

11,500

Interest Expense, Debt, Excluding Amortization

4,300

5,000

Interest Expense, Debt

16,100

17,500

16,500

Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost

4,300

Write off of Deferred Debt Issuance Cost

Amortization of Debt Issuance Costs

$ 619

$ 711

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 84.96

Number of Shares Underlying Warrants | shares

800,000

Convertible Notes, Due 2018 [Member] | Convertible Debt [Member] | Liability Component [Member]

Extinguishment of Debt, Amount

$ 189,000

Convertible Notes, Due 2018 [Member] | Convertible Debt [Member] | Equity Component [Member]

Extinguishment of Debt, Amount

5,800

Liability Component [Member] | Convertible Notes, Due 2018 [Member] | Convertible Debt [Member]

Equity Component [Member] | Convertible Notes, Due 2018 [Member] | Convertible Debt [Member]

$ 170,900

170,900

XML 82 R60.htm IDEA: XBRL DOCUMENT

$ 79,100

[1]	(1) Includes the $57.1 fully accreted amount of our 2018 Notes and $3.8 current maturities related to foreign facilities.
[2]	(1) During the year ended December 31, 2017, we wrote off $0.2 of unamortized debt issuance costs related to our senior secured revolving credit facility. When combined with the total loss on extinguishment associated with the 2018 Notes, consolidated loss on extinguishment is $4.9.

Debt And Credit Arrangements Senior Secured Revolving Credit Facility (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Amortization of Debt Issuance Costs	$ 1,279,000	$ 1,284,000	$ 1,290,000
Debt Instrument, Interest Rate, Stated Percentage	2.00%
Borrowings on revolving credit facilities	$ 302,200,000	3,800,000	$ 68,800,000
Senior Secured Revolving Credit Facility [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Term	5 years
Line of Credit Facility, Maximum Borrowing Capacity	$ 450,000,000
Long-term Debt, Gross		$ 0
Senior Secured Revolving Credit Facility, due 2022 [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Term	5 years
Line of Credit Facility, Maximum Borrowing Capacity	$ 450,000,000
Write off of Deferred Debt Issuance Cost	$ 200,000
Line of Credit Facility, Interest Rate Description	Revolving loans under the SSRCF bear interest, at the applicable Borrower’s election, at a rate per annum equal to either (i) the greatest of (a) the Prime Rate (as defined in the SSRCF) in effect on such day, (b) the NYFRB Rate (as defined in the SSRCF) in effect on such day plus 1/2 of 1.0% and (c) the Adjusted LIBOR (as defined in the SSRCF) for a one-month interest period on such day (or if such day is not a business day, the immediately preceding business day) plus 1.0% (the “Adjusted Base Rate”), plus a margin that varies with the Company’s leverage ratio, or (ii) the Adjusted LIBOR (as defined in the SSRCF) for the relevant interest period in effect for day, plus a margin that varies with our leverage ratio.
Debt Instrument, Covenant Description	Significant financial covenants for the SSRCF include a minimum liquidity requirement equal to the principal amount of the 2018 Notes outstanding six months prior to the maturity date of the 2018 Notes and when holders of the 2018 Notes have the option to require us to repurchase the 2018 Notes, a maximum leverage ratio of 3.25 and a minimum interest coverage to EBITDA ratio of 3.0. The required leverage ratio can be relaxed on up to two occasions, upon notification to the lenders, to 3.75 for up to four consecutive fiscal quarters, for acquisitions and plant expansions of $100.0 or greater. The SSRCF contains a number of other customary covenants including, but not limited to, restrictions on our ability to incur additional indebtedness, create liens or other encumbrances, sell assets, enter into sale and lease-back transactions, make certain payments, investments, loans, advances or guarantees, make acquisitions and engage in mergers or consolidations and pay dividends or distributions. At December 31, 2017, we were in compliance with all covenants.
Debt Instrument, Covenant Compliance	At December 31, 2017, we were in compliance with all covenants.
Debt Issuance Costs, Gross	$ 1,600,000
Unamortized Debt Issuance Expense	2,400,000
Amortization of Debt Issuance Costs	600,000
Long-term Debt, Gross	$ 239,000,000
Debt Instrument, Interest Rate, Stated Percentage	4.00%
Borrowings on revolving credit facilities	$ 300.0
Interest Expense, Debt	2,700,000
Letters of Credit Outstanding, Amount	42,900,000
Line of Credit Facility, Remaining Borrowing Capacity	$ 168,100,000
Maximum Percentage Of Capital Stock Guaranteed By Company's Material Non-U.S. Subsidiaries For Obligations Under The Senior Credit Facility	65.00%
Senior Secured Revolving Credit Facility, due 2022 [Member] \| Revolving Credit Facility [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.20%
Line of Credit, Participation Fee Percentage	1.50%
Senior Secured Revolving Credit Facility, due 2022 [Member] \| Revolving Credit Facility [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.375%
Line of Credit, Participation Fee Percentage	2.50%
Senior Secured Revolving Credit Facility, due 2022 [Member] \| Revolving Credit Facility Sub-limit - Swingline [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000,000
Senior Secured Revolving Credit Facility, due 2022 [Member] \| Revolving Credit Facility Sub-limit - Letters of Credit [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	100,000,000
Senior Secured Revolving Credit Facility, due 2022 [Member] \| Revolving Credit Facility Sub-limit - Foreign Currency [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	100,000,000
Senior Secured Revolving Credit Facility, due 2022 [Member] \| Revolving Credit Facility Sub-limit - Foreign Borrower [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	100,000,000
Senior Secured Revolving Credit Facility, due 2022 [Member] \| Revolving Credit Facility Sub-limit - Expansion Option [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 225,000,000
Revolving Credit Facility [Member] \| Senior Secured Revolving Credit Facility, due 2022 [Member]
Debt Instrument [Line Items]
Fronting Fee Percentage Charged For Issuance Of Letters Of Credit	0.125%

XML 83 R61.htm IDEA: XBRL DOCUMENT

Debt And Credit Arrangements Foreign Facilities (Details) € in Millions, ¥ in Millions, CZK in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2017 CNY (¥)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 CZK	Dec. 31, 2017 EUR (€)	Dec. 31, 2016 USD ($)
Debt Instrument [Line Items]
Short-term Debt		$ 58.9			$ 6.5
Debt Instrument, Face Amount		250.0
China Facilities [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	¥ 50.0	7.7
CCDEC Facility [Member] \| Line of Credit - Working Capital [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	30.0	4.6
Short-term Debt	¥ 2.3	$ 15.0
Short-term Debt, Weighted Average Interest Rate, at Point in Time	4.35%	4.35%	4.35%	4.35%
CCESC Term Loan Maturing May 26, 2024 [Member] \| Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	¥ 86.6	$ 13.3
Debt Instrument, Periodic Payment, Principal \| ¥	10.0
Long-term Debt	¥ 36.6	$ 5.6
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate	5.39%	5.39%	5.39%	5.39%
Ferox Secured Facility A1 Facility [Member] \| Secured Debt [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 5.9	CZK 125.0
Ferox Secured Facility A1 Facility [Member] \| Secured Debt [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Letter Of Credit And Guarantee Fees Percentage Of Face Amount For Maturities Up To One Year	0.50%	0.50%	0.50%	0.50%
Ferox Secured Facility B2facilities [Member] \| Secured Debt [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 6.7		€ 5.6
Ferox Secured Facility B2facilities [Member] \| Secured Debt [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Letter Of Credit And Guarantee Fees Percentage Of Face Amount For Maturities Up To One Year	0.70%	0.70%	0.70%	0.70%
Ferox Secured Facilities A and B Member [Member] \| Secured Debt [Member]
Debt Instrument [Line Items]
Bank Guarantees Supported By Credit Facilities		$ 7.0	CZK 147.8
Chart Luxembourg Facility [Member] \| Overdraft Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		5.0
Chart Cryogenic Engineering Systems Co., Ltd. [Member] \| China Facilities [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Bank Guarantees Supported By Credit Facilities	¥ 1.6	$ 0.3

XML 84 R62.htm IDEA: XBRL DOCUMENT

Debt And Credit Arrangements Scheduled Annual Maturities (Details) - USD ($)
$ in Millions

Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months

Long-term Debt, Maturities, Repayments of Principal in Year Two

$ 60.9

4.1

Long-term Debt, Maturities, Repayments of Principal in Year Five

239.0

Long-term Debt, Maturities, Repayments of Principal after Year Five

258.8

Long Term Debt Maturities Total Repayments Due

Convertible Notes, Due 2018 [Member]

Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months

57.1

Foreign Facilities [Member]

Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months

$ 3.8

[1]	(1) Includes the $57.1 fully accreted amount of our 2018 Notes and $3.8 current maturities related to foreign facilities.

XML 85 R63.htm IDEA: XBRL DOCUMENT

Debt And Credit Arrangements Letters of Credit (Details) - Energy & Chemicals [Member] $ in Millions	Dec. 31, 2017 USD ($)
Debt Instrument [Line Items]
Restricted Cash and Investments, Noncurrent	$ 6.4
Other Current Assets [Member]
Debt Instrument [Line Items]
Restricted Cash and Investments, Noncurrent	5.4
Other Assets [Member]
Debt Instrument [Line Items]
Restricted Cash and Investments, Noncurrent	$ 1.0

XML 86 R64.htm IDEA: XBRL DOCUMENT

Debt And Credit Arrangements Fair Value Disclosures about Debt (Details)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Debt Instrument, Fair Value Disclosure, Narrative	The fair value of the 2024 Notes was approximately 105% of their par value as of December 31, 2017. The fair value of the 2018 Notes was approximately 99% of their par value as of December 31, 2017 and approximately 96% of their par value as of December 31, 2016. The 2024 Notes and 2018 Notes are actively quoted instruments and, accordingly, the fair values of the 2024 Notes and 2018 Notes were determined using Level 1 inputs as defined in Note 11.

XML 87 R65.htm IDEA: XBRL DOCUMENT

Financial Instruments and Derivative Financial Instruments Concentration of Credit Risks (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Derivative [Line Items]
Concentration Risk, Customer Balance	$ 98.9
Concentration Risk, Benchmark Description	No single customer exceeded ten percent of consolidated sales in 2017.	One customer exceeded ten percent of consolidated sales in 2016.	No single customer exceeded ten percent of consolidated sales in 2015.
Geographic Concentration Risk [Member]
Derivative [Line Items]
Concentration Risk, Percentage	47.00%	50.00%	51.00%
Customer Concentration Risk [Member]
Derivative [Line Items]
Concentration Risk, Percentage	35.00%	38.00%	36.00%

XML 88 R66.htm IDEA: XBRL DOCUMENT

Financial Instruments and Derivative Financial Instruments Foreign Currency Forward Contracts (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Derivative [Line Items]
Gain (Loss) on Foreign Currency Fair Value Hedge Derivatives	$ 0.5	$ (0.8)	$ 2.7

XML 89 R67.htm IDEA: XBRL DOCUMENT

Product Warranties (Details) - USD ($) $ in Millions	12 Months Ended
Product Warranties (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Product Warranty Liability [Line Items]
Standard Product Warranty Accrual Beginning	$ 18.3	$ 21.0	$ 24.2
Standard Product Warranty Accrual, Warranties Issued	7.1	8.8	13.7
Standard Product Warranty Accrual, Additions from Business Acquisition	0.9	0.0	0.0
Standard Product Warranty Accrual, Period Increase (Decrease)	2.1	1.2	3.0
Standard Product Warranty Accrual, Payments	(11.7)	(12.7)	(19.9)
Standard Product Warranty Accrual Ending	$ 16.7	18.3	$ 21.0
BioMedical [Member] \| Cost of Sales [Member]
Product Warranty Liability [Line Items]
Product Warranty Expense		$ 15.2

XML 90 R68.htm IDEA: XBRL DOCUMENT

Business Combinations Hudson Narrative (Details) - USD ($)
$ in Millions

Borrowings on revolving credit facilities

Business Combination, Acquisition Related Costs

Business Combination, Consideration Transferred

419.5

Business Combination Consideration Transferred Estimated Working Capital Amount credit

6.0

Business Combination, Consideration Transferred, Acquisition-related Tax Benefits (credit)

3.5

Borrowings on revolving credit facilities

Business Combination, Acquisition Related Costs

$ 9.0

Minimum [Member]

Finite-Lived Intangible Asset, Useful Life

10 years

Minimum [Member] | Hudson [Member]

Finite-Lived Intangible Asset, Useful Life

2 years

Maximum [Member] | Hudson [Member]

Finite-Lived Intangible Asset, Useful Life

15 years

[1]	Hudson, included in these results since the acquisition date, September 20, 2017, added net sales and operating income of $58.0 and $6.4 for the year ended December 31, 2017, including $6.1 and $1.2 in the third quarter and $51.9 and $5.2 in the fourth quarter, respectively.
[2]	The fourth quarter of 2017 includes additional expense as a result of a litigation award in China. Refer to Note 18, Commitments and Contingencies, for further information.
[3]	During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes impairment of goodwill and intangible assets totaling $1.2 as described in Note 3, Asset Impairments, to the consolidated financial statements.
[4]	Includes acquisition-related expenses of $10.1 for the year ended December 31, 2017.
[5]	Includes restructuring costs of $15.6, $10.9 and $12.2 for the years ended December 31, 2017, 2016 and 2015, respectively
[6]	During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes asset impairment charges of $1.2 attributed to D&S.
[7]	Includes asset impairment charges of $255.1 for the year ended December 31, 2015, attributed to E&C – $68.8, D&S – $2.0, and BioMedical – $184.3.

XML 91 R69.htm IDEA: XBRL DOCUMENT

Business Combinations Hudson Net Assets Acquired (Details) - USD ($)
$ in Millions

Restricted Cash and Cash Equivalents

8.8

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill

Goodwill

238.3

$ 227.4

10.9

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

211.0

202.0

$ 211.0

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles

9.0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

34.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

29.4

30.6

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

26.5

24.9

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory

1.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other

8.1

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other current assets

9.3

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Unbilled Contract Revenue

4.9

4.6

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Unbilled contract revenue

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets

2.9

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets

0.9

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

87.6

68.6

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred tax liabilities

19.0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable

21.2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Advances and Billings In Excess of Contract Revenue

17.4

16.9

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Customer advances and billings in excess of contract revenue

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Accrued Salaries Wages and Benefits

4.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other

3.8

4.0

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other current liabilities

0.2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Current portion of warranty reserve

0.8

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net

419.5

$ 419.4

Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net

$ 0.1

Restricted Cash and Cash Equivalents

$ 2.3

[1]

(1) Pursuant to the provisions of the Merger Agreement, Hudson deposited $2.3 into a Rabbi Trust which represents amounts payable to eligible parties under Long-Term Incentive Agreements. This balance is treated as restricted cash and restricted cash equivalents in the consolidated balance sheets and is classified as other current assets.

XML 92 R70.htm IDEA: XBRL DOCUMENT

Business Combinations Hudson Intangible Assets Acquired (Details) - USD ($)
$ in Millions

Acquired Finite-Lived Intangible Assets [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

14 years

Customer Relationships [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

12 years

Unpatented Technology [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

12 years

Acquired Finite-Lived Intangible Assets [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

12 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 141.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets

69.3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill

$ 211.0

$ 202.0

211.0

Hudson [Member] | Customer Relationships [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

13 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

122.1

Hudson [Member] | Unpatented Technology [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

10 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

18.3

Hudson [Member] | Order or Production Backlog [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

2 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

XML 93 R71.htm IDEA: XBRL DOCUMENT

$ 1.3

[1]	(1) Customer backlog acquired is included in “Patents and other” in Note 6. Goodwill and Intangible Assets.

Business Combinations Hudson Supplemental Pro Forma Information (Details) - Hudson [Member] - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Pro Forma Adjustment, nonrecurring acquisition-related expenses incurred by Hudson	$ 16.5
Pro Forma Adjustment, nonrecurring acquisition-related expenses incurred by Chart	9.0
Business Acquisition, Pro Forma Revenue	1,130.0	$ 1,029.0
Business Acquisition, Pro Forma Net Income (Loss)	$ 16.8	$ 17.1
Business Acquisition, Pro Forma Earnings Per Share, Basic	$ 0.55	$ 0.56
Business Acquisition, Pro Forma Earnings Per Share, Diluted	$ 0.54	$ 0.55

XML 94 R72.htm IDEA: XBRL DOCUMENT

Business Combinations VCT Vogel GmbH (Details) - VCT Vogel GmbH [Member] € in Millions, $ in Millions	Aug. 31, 2017 USD ($)	Aug. 31, 2017 EUR (€)
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%	100.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	$ 4.2	€ 3.6
VCT Vogel Purchase Price Hold Back Amount	$ 0.4	€ 0.4

XML 95 R73.htm IDEA: XBRL DOCUMENT

Business Combinations Hetsco Acquisition (Details) - USD ($) $ in Millions	9 Months Ended
	Dec. 31, 2017	Mar. 31, 2017	Jan. 13, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 468.8			$ 218.0	$ 218.4
Hetsco [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired			100.00%
Goodwill	8.8	$ 10.1
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill	(1.3)
Customer relationships acquired	8.1	7.3
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles	0.8
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	1.2	1.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	4.7	4.6
Business Combination Provisional Information Initial Accounting Incomplete, other net assets	0.1
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	22.8	$ 23.2
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	$ (0.4)

XML 96 R74.htm IDEA: XBRL DOCUMENT

Business Combinations Contingent Consideration (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Combination, Contingent Consideration, Liability	$ 0.3	$ 1.9	$ 1.8	$ 1.1
Business Combination, Contingent Consideration, Inception Amount Recorded During Reporting Period	1.8		1.8
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	1.6	0.1	0.5
Payment for Contingent Consideration Liability, Investing Activities			0.6
Minimum [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	0.0
Maximum [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	11.3
Distribution & Storage [Member]
Business Combination, Contingent Consideration, Liability	0.3	1.9	1.8	0.0
Business Combination, Contingent Consideration, Inception Amount Recorded During Reporting Period			1.8
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	1.6	0.1	0.0
Payment for Contingent Consideration Liability, Investing Activities			0.0
BioMedical [Member]
Business Combination, Contingent Consideration, Liability	0.0	0.0	0.0	$ 1.1
Business Combination, Contingent Consideration, Inception Amount Recorded During Reporting Period			0.0
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ 0.0	$ 0.0	0.5
Payment for Contingent Consideration Liability, Investing Activities			$ 0.6

XML 97 R75.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($) $ in Millions	12 Months Ended
Fair Value Measurements (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency forward contracts	$ 0.1
Total financial assets	0.1
Foreign currency forward contracts		$ 0.1
Contingent consideration liabilities	0.3	1.9
Total financial liabilities	0.3	2.0
Asset impairments	0.0	1.2	$ 253.6
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency forward contracts	0.1
Total financial assets	0.1
Foreign currency forward contracts		0.1
Contingent consideration liabilities	0.0	0.0
Total financial liabilities	0.0	0.1
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency forward contracts	0.0
Total financial assets	0.0
Foreign currency forward contracts		0.0
Contingent consideration liabilities	0.3	1.9
Total financial liabilities	$ 0.3	$ 1.9

XML 98 R76.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions

Accumulated Other Comprehensive Income (Loss) [Line Items]

Accumulated Other Comprehensive Income (Loss), Net of Tax Beginning

$ (35.2)

$ (24.9)

OCI, before Reclassifications, Net of Tax, Attributable to Parent

25.0

(11.3)

Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent

2.1

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent

27.1

(10.3)

Accumulated Other Comprehensive Income (Loss), Net of Tax Ending

(8.1)

(35.2)

Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax

2.9

0.6

Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent

0.4

Accumulated Foreign Currency Adjustment Attributable to Parent [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Accumulated Other Comprehensive Income (Loss), Net of Tax Beginning

(24.7)

(12.5)

OCI, before Reclassifications, Net of Tax, Attributable to Parent

25.6

(12.2)

Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent

1.3

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent

26.9

(12.2)

Accumulated Other Comprehensive Income (Loss), Net of Tax Ending

2.2

(24.7)

Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Accumulated Other Comprehensive Income (Loss), Net of Tax Beginning

(10.5)

(12.4)

OCI, before Reclassifications, Net of Tax, Attributable to Parent

(0.5)

0.9

Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent

^[2]

0.8

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent

Accumulated Other Comprehensive Income (Loss), Net of Tax Ending

(10.2)

(10.5)

Selling, General and Administrative Expenses [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax

0.7

0.9

Cost of Sales [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax

$ 0.5

$ 0.6

[1]	For the year ended December 31, 2017, $1.3 was reclassified from accumulated other comprehensive loss to foreign currency loss in the consolidated statements of operations and comprehensive income related to certain intercompany transactions.
[2]	Amounts reclassified from accumulated other comprehensive loss were expensed and included in cost of sales ($0.5 and $0.6 for the years ended December 31, 2017 and 2016, respectively) and selling, general and administrative expenses ($0.7 and $0.9 for the years ended December 31, 2017 and 2016, respectively) in the consolidated statements of operations.

XML 99 R77.htm IDEA: XBRL DOCUMENT

Earnings Per Share Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions

Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]

Net income (loss) attributable to Chart Industries, Inc.

Weighted Average Number of Shares Outstanding, Basic

^[4]

30,740

30,580

30,490

Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements

600

410

Weighted Average Number of Shares Outstanding, Diluted

31,340

30,990

30,490

[1]	During the fourth quarter of 2017, we recorded a $4.9 loss on extinguishment of debt associated with the repurchase of $192.9 principal amount of our $250.0 2.00% convertible notes due August 2018 and refinance of our senior secured revolving credit facility.
[2]	The fourth quarter of 2017 includes a one-time $22.5 net favorable tax benefit that was recorded during the fourth quarter of 2017, which resulted from the enactment of the Tax Cuts and Jobs Act. This benefit mainly consisted of a one-time, provisional benefit of $26.9 related to the remeasurement of certain of our deferred tax liabilities using the lower U.S. federal corporate tax rate of 21%. This was partially offset by (i) a one-time, provisional charge of $8.7 related to the deemed repatriation transition tax, which is a tax on previously untaxed accumulated earnings and profits of certain of our foreign subsidiaries, and (ii) a one-time tax expense and tax benefit of $4.5 and $8.7, respectively, related to our intent to amend pre-acquisition Hudson U.S. federal tax returns.
[3]	Basic and diluted (loss) earnings per share are computed independently for each of the quarters presented. As such, the sum of quarterly basic and diluted (loss) earnings per share may not equal reported annual basic and diluted (loss) earnings per share.
[4]	Basic and diluted (loss) earnings per share are computed independently for each of the quarters presented. As such, the sum of quarterly basic and diluted (loss) earnings per share may not equal reported annual basic and diluted (loss) earnings per share.
[5]	Zero incremental shares from share-based awards are included in the computation of diluted net loss per share for periods in which a net loss occurs, because to do so would be anti-dilutive.
[6]	Zero incremental shares from share-based awards are included in the computation of diluted net loss per share for periods in which a net loss occurs, because to do so would be anti-dilutive.

XML 100 R78.htm IDEA: XBRL DOCUMENT

Earnings Per Share Antidilutive Securities (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,580	3,930	4,310
Stock Incentive Plans [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	400	560	940
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,180	3,370	3,370

XML 101 R79.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Contingency [Line Items]
Income Tax Examination, Penalties and Interest Accrued	$ 0.1	$ 0.1
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount	(26.9)	0.0	$ 0.0
Income Tax Expense (Benefit)	(15.9)	13.7	2.7
Income before taxes
United States	2.7	40.5	(187.2)
Foreign	10.9	(2.1)	(14.6)
Income (loss) before income taxes	13.6	38.4	(201.8)
Current:
Federal	6.1	10.0	22.9
State	0.5	1.0	1.1
Foreign	7.3	5.3	3.1
Current income tax expense (benefit)	13.9	16.3	27.1
Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]
Federal	(28.8)	(3.3)	(25.7)
State and local	(0.4)	(0.2)	(0.6)
Foreign	(0.6)	0.9	1.9
Deferred income tax expense (benefit)	(29.8)	(2.6)	(24.4)
Effective Tax Rate Reconciliation
Income tax expense (benefit) at U.S. statutory rate	4.8	13.4	(70.6)
State income taxes, net of federal tax benefit	0.6	0.7	0.4
Foreign income, net of credit on foreign taxes	8.8	0.2	0.0
Effective tax rate differential of earnings outside of U.S.	(0.5)	0.5	0.0
Change in valuation allowance	7.8	6.6	(5.6)
Research & experimentation credits	(0.6)	(0.9)	(0.9)
Non-deductible items	0.6	0.7	2.7
Change in uncertain tax positions	0.1	(0.2)	0.1
Domestic production activities deduction	(0.4)	(1.2)	(2.1)
Tax effect of asset impairments	0.0	0.0	67.3
Effective Income Tax Rate Reconciliation, Insurance Proceeds	0.0	(5.8)	0.0
Deferred Tax Assets, Tax Credit Carryforwards, Foreign	(10.3)	0.0	0.0
Other items	0.1	(0.3)	0.2
Deferred tax assets:
Accruals and reserves	11.8	24.1
Pensions	2.0	5.3
Inventory	4.3	6.8
Stock options	6.6	9.4
Tax credit carryforwards	16.4	2.2
Foreign net operating loss carryforwards	12.4	5.9
State net operating loss carryforward	2.0	1.6
Other - net	0.2	0.9
Total deferred tax assets before valuation allowance	55.7	56.2
Valuation allowance	(27.2)	(15.1)
Total deferred tax assets, net of valuation allowance	28.5	41.1
Deferred tax liabilities:
Property, plant and equipment	15.0	19.4
Intangibles	72.9	22.9
Deferred Tax Liabilities, Convertible Notes	(0.5)	1.0
Deferred Tax Liabilities, Other	2.9	0.0
Deferred Tax Liabilities, Gross, Noncurrent	90.3	43.3
Total deferred tax liabilities	61.8	2.2
Deferred Tax Assets, Net, Noncurrent	(0.7)	(2.0)
Long-term deferred tax liabilities	62.5	4.2
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized Tax Benefits Ending Balance Beginning	0.8	1.0	0.9
Additions for tax positions of prior years	0.1	0.0	0.1
Reductions for tax positions of prior years	(0.1)	0.0	0.0
Lapse of statutes of limitation	0.0	(0.2)	0.0
Unrecognized Tax Benefits Ending Balance Ending	0.8	0.8	1.0
Undistributed Earnings of Foreign Subsidiaries		190.4
Tax Cuts and Jobs Act Undistributed Foreign Earnings	200.0
Foreign Earnings Repatriated	50.0
Income Taxes Paid	15.4	17.6	$ 30.5
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	0.6	$ 0.6
Net favorable tax benefit due to tax reform	22.5
Deferred income taxes, Deferred tax liabilities provisional decrease	$ (26.9)
Effective income tax rate Jan 1 2018 after tax reform	21.00%
Provisional Tax Expense for Repatriation Transition Tax	$ 8.7
One time tax expense, intent to amend Hudson returns	4.5
One time tax benefit, intent to amend Hudson returns	8.7
Deferred income taxes, Deferred tax liabilities provisional decrease due to tax reform	$ (26.9)

XML 102 R80.htm IDEA: XBRL DOCUMENT

Income Taxes Operating Loss Carryforwards (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
State net operating losses usable after limitations from Internal Revenue Code 382	$ 15.9
Deferred Tax Assets, Operating Loss Carryforwards, State and Local, Gross	2.5
Valuation allowance	27.2	$ 15.1
Foreign net operating loss carryforwards	12.4	$ 5.9
Investment Tax Credit	1.0
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Valuation allowance	2.2
Foreign Country [Member]
Operating Loss Carryforwards [Line Items]
Valuation allowance	12.1
Foreign operating losses available to carryforward	70.8
Foreign operating losses expiring between 2014 and 2016	67.6
Foreign operating losses to be carried forward indefinitely	$ 3.2

XML 103 R81.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans Employee Benefit Plans - Various (Details) - USD ($)
$ in Millions

Components of net periodic pension expense:

Interest cost

$ 2.2

$ 2.3

Expected return on plan assets

(2.8)

(3.2)

Amortization of net loss

Total net periodic pension expense

1.5

1.4

0.6

Change in projected benefit obligation:

Projected benefit obligation at beginning of year

Defined Benefit Plan, Benefit Obligation, Benefits Paid

(2.3)

(3.9)

Actuarial gains (losses)

1.6

(1.2)

Projected benefit obligation at year end

57.0

55.5

58.3

Employer contributions

3.0

Funded status (Accrued pension liabilities) (1)

48.5

41.1

$ 41.0

(8.5)

Unrecognized actuarial loss recognized in accumulated other comprehensive loss

(14.4)

13.2

$ 16.7

Defined Benefit Plan, Amortization of Net Gains (Losses)

$ 0.9

Assumptions used to determine benefit obligation at year end:

Discount rate

3.70%

4.00%

Assumptions used to determine net periodic benefit cost:

Discount rate

4.00%

3.80%

Expected long-term weighted-average rate of return on plan assets

7.00%

7.30%

Expected future benefit payments

Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months

$ 2.6

Defined Benefit Plan, Expected Future Benefit Payment, Year Two

2.8

Defined Benefit Plan, Expected Future Benefit Payment, Year Three

2.9

Defined Benefit Plan, Expected Future Benefit Payment, Year Four

3.0

Defined Benefit Plan, Expected Future Benefit Payment, Year Five

3.1

In aggregate during five years thereafter

16.6

Multiemployer Plan, Contributions by Employer

Defined contribution expense

$ 0.7

9.7

10.0

10.8

Deferred Compensation Arrangement with Individual, Compensation Expense

Equity Funds [Member]

28.1

Fixed Income Funds [Member]

33.0

28.1

11.7

Other Investments [Member]

12.6

11.7

1.3

Minimum [Member] | Equity Funds [Member]

$ 2.9

$ 1.3

Minimum [Member] | Fixed Income Funds [Member]

60.00%

Minimum [Member] | Other Investments [Member]

26.00%

Maximum [Member] | Equity Funds [Member]

3.00%

Maximum [Member] | Fixed Income Funds [Member]

68.00%

Maximum [Member] | Other Investments [Member]

30.00%

XML 104 R82.htm IDEA: XBRL DOCUMENT

6.00%

[1]	(1) Accrued pension liabilities on the December 31, 2017 consolidated balance sheet includes $0.9 related to Hudson, which is not included in the table above.

Employee Benefit Plans Defined Benefit Plan - Plan Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	$ 48.5	$ 41.1	$ 41.0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Beginning Balance	1.3	0.3
Purchases, sales and settlements, net	(2.4)	(4.2)
Transfers, net	4.0	5.2
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Ending Balance	2.9	1.3
Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	45.6	39.8
Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	2.9	1.3
Equity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	33.0	28.1
Equity Funds [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	33.0	28.1
Equity Funds [Member] \| Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	0.0	0.0
Fixed Income Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	12.6	11.7
Fixed Income Funds [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	12.6	11.7
Fixed Income Funds [Member] \| Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	0.0	0.0
Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	2.9	1.3
Other Investments [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	0.0	0.0
Other Investments [Member] \| Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Fair Value of Plan Assets	$ 2.9	$ 1.3
Minimum [Member] \| Equity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Allocation Percentage	60.00%
Minimum [Member] \| Fixed Income Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Allocation Percentage	26.00%
Minimum [Member] \| Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Allocation Percentage	3.00%
Maximum [Member] \| Equity Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Allocation Percentage	68.00%
Maximum [Member] \| Fixed Income Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Allocation Percentage	30.00%
Maximum [Member] \| Other Investments [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Target Allocation Percentage	6.00%

XML 105 R83.htm IDEA: XBRL DOCUMENT

Employee Benefit Plans Hudson Defined Benefit Plan (Details) - USD ($)
$ in Millions

Defined Benefit Plan, Benefit Obligation

Dec. 31, 2015

$ 57.0

$ 55.5

$ 58.3

Defined Benefit Plan, Fair Value of Plan Assets

(48.5)

(41.1)

$ (41.0)

Defined Benefit Plan, Funded (Unfunded) Status of Plan

(8.5)

$ (14.4)

Defined Benefit Plan, Benefit Obligation

2.8

Defined Benefit Plan, Fair Value of Plan Assets

(1.9)

Defined Benefit Plan, Funded (Unfunded) Status of Plan

XML 106 R84.htm IDEA: XBRL DOCUMENT

$ 0.9

[1]	(1) Accrued pension liabilities on the December 31, 2017 consolidated balance sheet includes $0.9 related to Hudson, which is not included in the table above.

Share-based Compensation Overall (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	$ 11.1	$ 10.7	$ 11.3
Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation		$ (1.7)	(0.9)
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 5.8
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	2 years 22 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,250	1,110
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 2.4
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	2 years 161 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested, shares	330	330
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 2.6
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	1 year 303 days
Performance units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested, shares		80
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 0.8
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	1 year 230 days
Leveraged Restricted Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested, shares	0	10
2017 Omnibus Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,700
Nonvested, shares	10
Omnibus Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,350
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,200
Omnibus Equity Plan [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested, shares	320
Omnibus Equity Plan [Member] \| Performance units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested, shares	80
Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,420
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	60
Additional Paid-in Capital [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation		$ (1.7)	$ (0.9)

XML 107 R85.htm IDEA: XBRL DOCUMENT

Share-based Compensation Stock Options (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	2 years 22 days
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 5.8
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value per share	$ 20.10	$ 10.36	$ 19.04
Expected term (years)	5 years 146 days	5 years 72 days	5 years 219 days
Risk-free interest rate	2.00%	1.66%	1.70%
Expected volatility	60.31%	61.40%	61.54%
Award vesting period	4 years
Contractual Term	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period, shares	1,110
Outstanding at beginning of period, price	$ 31.13
Granted, shares	320
Granted, price	$ 37.06
Exercised	(80)
Exercised, price	$ 25.71
Forfeited / Cancelled, shares	(100)
Forfeited / Cancelled, price	$ 36.16
Outstanding at end of period, shares	1,250	1,110
Outstanding at end of period, price	$ 32.58	$ 31.13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 21.9
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 157 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	1,240
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 32.60
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 9.4
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	6 years 146 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	560
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 36.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 21.7
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 245 days
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	2 years 161 days
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 2.4
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	1.2	$ 0.2	$ 0.7
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 3.4	$ 3.9	$ 3.6

XML 108 R86.htm IDEA: XBRL DOCUMENT

Share-based Compensation Restricted Stock (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	2 years 22 days
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 5.8
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Nonvested, shares	330	330
Nonvested, Weighted Average Grant Date Fair Value	$ 28.38	$ 24.06
Granted, shares	160
Granted, Weighted Average Grant Date Fair Value	$ 37.13	$ 19.08	$ 34.15
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(30)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 26.51
Vested, shares	(130)
Vested, Weighted Average Grant Date Fair Value	$ 28.52
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	1 year 303 days
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 2.6
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 4.8	$ 1.2	$ 1.6

XML 109 R87.htm IDEA: XBRL DOCUMENT

Share-based Compensation Performance Units (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	2 years 22 days
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 5.8
Performance units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Nonvested, shares		80
Nonvested, Weighted Average Grant Date Fair Value	$ 24.81	$ 31.84
Granted, shares	30
Granted, Weighted Average Grant Date Fair Value	$ 38.00	$ 19.94	$ 28.25
Vested, shares	(20)
Vested, Weighted Average Grant Date Fair Value	$ 93.34
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	1 year 230 days
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 0.8
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 0.8	$ 1.8	$ 0.8
Performance units [Member] \| 2015 PSU [Member] [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percent of Performance Share Units Earned Out Of Performance Share Units Granted	0.00%
Performance units [Member] \| 2015 PSU [Member] [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percent of Performance Share Units Earned Out Of Performance Share Units Granted	200.00%
Performance units [Member] \| 2016 PSU [Member] [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percent of Performance Share Units Earned Out Of Performance Share Units Granted	0.00%
Performance units [Member] \| 2016 PSU [Member] [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percent of Performance Share Units Earned Out Of Performance Share Units Granted	200.00%
Performance units [Member] \| 2017 Performance Units [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percent of Performance Share Units Earned Out Of Performance Share Units Granted	0.00%
Performance units [Member] \| 2017 Performance Units [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percent of Performance Share Units Earned Out Of Performance Share Units Granted	200.00%
Performance Based Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(10)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 31.14
Leveraged Restricted Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Nonvested, shares	0	10
Nonvested, Weighted Average Grant Date Fair Value	$ 0.00	$ 106.90
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(5)
Vested, shares	(5)
Vested, Weighted Average Grant Date Fair Value	$ 106.90
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 0.2	$ 1.0	$ 0.6

XML 110 R88.htm IDEA: XBRL DOCUMENT

Share-based Compensation Leveraged Restricted Share Awards (Details) - USD ($) $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Nonvested, shares	330	330
Nonvested, Weighted Average Grant Date Fair Value	$ 28.38	$ 24.06
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(30)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 26.51
Vested, shares	(130)
Vested, Weighted Average Grant Date Fair Value	$ 28.52
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 4,800,000	$ 1,200,000	$ 1,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	160
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 37.13	$ 19.08	$ 34.15
Leveraged Restricted Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Nonvested, shares	0	10
Nonvested, Weighted Average Grant Date Fair Value	$ 0.00	$ 106.90
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(5)
Share-Based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited, Weighted Average Grant Date Fair Value	$ 106.90
Vested, shares	(5)
Vested, Weighted Average Grant Date Fair Value	$ 106.90
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 200,000	$ 1,000,000	$ 600,000
Leveraged Restricted Share Awards [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percent of Leveraged Restricted Share Units Earned Out Of Leveraged Restricted Share Units Granted	50.00%
Leveraged Restricted Share Awards [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percent of Leveraged Restricted Share Units Earned Out Of Leveraged Restricted Share Units Granted	150.00%

XML 111 R89.htm IDEA: XBRL DOCUMENT

Share-based Compensation Directors' Stock Grants (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonemployee directors stock awards, Quantity of Securities Issued	20	30	20
Nonemployee directors stock awards, Amount recognized in equity	$ 0.7	$ 0.6	$ 0.7

XML 112 R90.htm IDEA: XBRL DOCUMENT

Lease Commitments (Details) - USD ($) $ in Millions	12 Months Ended
Lease Commitments (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Leases [Abstract]
Rental expense under operating leases	$ 11.5	$ 9.5	$ 11.1
Future minimum lease payments for non-cancelable operating leases
Operating Leases, Future Minimum Payments Due, Next Twelve Months	9.2
Operating Leases, Future Minimum Payments, Due in Two Years	7.1
Operating Leases, Future Minimum Payments, Due in Three Years	5.6
Operating Leases, Future Minimum Payments, Due in Four Years	4.1
Operating Leases, Future Minimum Payments, Due in Five Years	3.8
Operating Leases, Future Minimum Payments, Due Thereafter	10.8
Operating Leases, Future Minimum Payments Due	$ 40.6

XML 113 R91.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies Environmental (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accrual for Environmental Loss Contingencies	$ 2.1	$ 3.0
Number of years expected for future environmental remediation expenditures duration	10 years
Accrual for Environmental Loss Contingencies, Significant Assumptions	We accrue for certain environmental remediation-related activities for which commitments or remediation plans have been developed and for which costs can be reasonably estimated. These estimates are determined based upon currently available facts and circumstances regarding each facility. Actual costs incurred may vary from these estimates due to the inherent uncertainties involved. Future expenditures relating to these environmental remediation efforts are expected to be made over the next 10 years as ongoing costs of remediation programs.

XML 114 R92.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies Legal Proceedings (Details) - 12 months ended Dec. 31, 2017 ¥ in Millions, $ in Millions	CNY (¥)	USD ($)	USD ($)
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	¥ 64.8	$ 9.9
Loss Contingency, Estimate of Possible Loss	30.0		$ 4.6
Loss Contingency Accrual	53.9		$ 8.3
Loss Contingency Accrual, Period Increase (Decrease)	¥ 23.9	$ 3.7

XML 115 R93.htm IDEA: XBRL DOCUMENT

Restructuring Activities Restructuring Charges (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Severance Costs	$ 4.6	$ 10.0	$ 7.4
Other Restructuring Costs	11.0	0.9	4.8
Restructuring Costs	15.6	10.9	12.2
Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Severance Costs	0.8	4.2	2.2
Other Restructuring Costs	4.4	0.2	1.4
Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Severance Costs	3.8	5.8	5.2
Other Restructuring Costs	$ 6.6	$ 0.7	$ 3.4

XML 116 R94.htm IDEA: XBRL DOCUMENT

Restructuring Activities Restructuring Accruals (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve Beginning	$ 7.3	$ 5.8	$ 0.0
Restructuring Costs	15.6	10.9	12.2
Payments for Restructuring	(20.3)	(9.4)	(6.4)
Restructuring Reserve, Period Increase (Decrease)	0.2
Restructuring Reserve Ending	2.8	7.3	5.8
Energy & Chemicals [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve Beginning	0.1	1.1	0.0
Restructuring Costs	2.4	1.0	1.4
Payments for Restructuring	(2.5)	(2.0)	(0.3)
Restructuring Reserve, Period Increase (Decrease)	0.2
Restructuring Reserve Ending	0.2	0.1	1.1
Distribution & Storage [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve Beginning	2.9	3.4	0.0
Restructuring Costs	2.2	3.8	7.7
Payments for Restructuring	(3.9)	(4.3)	(4.3)
Restructuring Reserve, Period Increase (Decrease)	0.0
Restructuring Reserve Ending	1.2	2.9	3.4
BioMedical [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve Beginning	1.3	0.4	0.0
Restructuring Costs	5.0	1.9	1.8
Payments for Restructuring	(6.0)	(1.0)	(1.4)
Restructuring Reserve, Period Increase (Decrease)	0.0
Restructuring Reserve Ending	0.3	1.3	0.4
Corporate Segment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve Beginning	3.0	0.9	0.0
Restructuring Costs	6.0	4.2	1.3
Payments for Restructuring	(7.9)	(2.1)	(0.4)
Restructuring Reserve, Period Increase (Decrease)	0.0
Restructuring Reserve Ending	$ 1.1	$ 3.0	$ 0.9

XML 117 R95.htm IDEA: XBRL DOCUMENT

Segment and Geographic Information Segment and Geographic Information (Details) - USD ($)
$ in Millions

$ 988.8

$ 859.2

$ 1,040.2

41.9

37.5

45.4

Acquisition-related expenses

Asset Impairments Charges and Other PP&E Impairment

Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure

255.1

98.9

United States [Member]

526.7

426.0

513.7

110.0

147.7

110.0

Czech Republic [Member]

Other Non-U.S. Countries [Member]

352.1

285.5

416.5

Non-U.S. Countries [Member]

462.1

433.2

526.5

Energy & Chemicals [Member]

225.6

154.3

331.0

15.3

10.0

11.8

Asset Impairments Charges and Other PP&E Impairment

68.8

Energy & Chemicals [Member] | Natural gas processing (including petrochemical) applications [Member]

Energy & Chemicals [Member] | Liquefied natural gas applications [Member]

152.9

105.4

180.9

Energy & Chemicals [Member] | Industrial gas applications [Member]

29.5

38.2

136.1

Energy & Chemicals [Member] | HVAC, power and refining [Member]

22.4

10.7

14.0

20.8

Distribution & Storage [Member]

540.3

497.1

487.6

18.8

18.4

18.3

Asset Impairments Charges and Other PP&E Impairment

Distribution & Storage [Member] | Liquefied natural gas applications [Member]

2.0

Distribution & Storage [Member] | Bulk industrial gas applications [Member]

137.7

109.8

115.9

Distribution & Storage [Member] | Packaged gas industrial applications [Member]

221.9

227.6

203.9

222.9

207.8

221.6

5.6

6.0

12.0

Asset Impairments Charges and Other PP&E Impairment

184.3

BioMedical [Member] | Respiratory therapy [Member]

BioMedical [Member] | Cryobiological storage [Member]

124.4

118.9

132.3

BioMedical [Member] | On-site generation systems [Member]

77.0

70.6

64.6

2.2

3.1

3.3

Cost of Sales [Member] | BioMedical [Member]

Selling, General and Administrative Expenses [Member] | BioMedical [Member]

Product Warranty Expense

15.2

XML 118 R96.htm IDEA: XBRL DOCUMENT

[1]	Hudson, included in these results since the acquisition date, September 20, 2017, added net sales and operating income of $58.0 and $6.4 for the year ended December 31, 2017, including $6.1 and $1.2 in the third quarter and $51.9 and $5.2 in the fourth quarter, respectively.
[2]	The fourth quarter of 2017 includes additional expense as a result of a litigation award in China. Refer to Note 18, Commitments and Contingencies, for further information.
[3]	During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes impairment of goodwill and intangible assets totaling $1.2 as described in Note 3, Asset Impairments, to the consolidated financial statements.
[4]	Includes acquisition-related expenses of $10.1 for the year ended December 31, 2017.
[5]	Includes restructuring costs of $15.6, $10.9 and $12.2 for the years ended December 31, 2017, 2016 and 2015, respectively
[6]	During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes asset impairment charges of $1.2 attributed to D&S.
[7]	Includes asset impairment charges of $255.1 for the year ended December 31, 2015, attributed to E&C – $68.8, D&S – $2.0, and BioMedical – $184.3.

Quarterly Data (unaudited) (Details) - USD ($)
$ / shares in Units, $ in Millions

Net income attributable to Chart Industries, Inc.

Debt Instrument, Repurchase Amount

$ 4.9

$ 0.0

192.9

Debt Instrument, Interest Rate, Stated Percentage

$ 250.0

2.00%

Income Tax Expense (Benefit)

$ (15.9)

13.7

2.7

Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax

4.5

Income Tax Expense (Benefit)

$ (26.9)

Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent

21.00%

Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount

$ 5.2

$ 1.2

6.4

Cost of Sales [Member]

Asset impairments

1.5

BioMedical [Member]

BioMedical [Member] | Cost of Sales [Member]

35.5

42.0

$ (165.3)

Product Warranty Expense

15.2

BioMedical [Member] | Selling, General and Administrative Expenses [Member]

Income Tax Expense (Benefit)

$ 8.7

[1]	Hudson, included in these results since the acquisition date, September 20, 2017, added net sales and operating income of $58.0 and $6.4 for the year ended December 31, 2017, including $6.1 and $1.2 in the third quarter and $51.9 and $5.2 in the fourth quarter, respectively.
[2]	The fourth quarter of 2017 includes additional expense as a result of a litigation award in China. Refer to Note 18, Commitments and Contingencies, for further information.
[3]	During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes impairment of goodwill and intangible assets totaling $1.2 as described in Note 3, Asset Impairments, to the consolidated financial statements.
[4]	Includes acquisition-related expenses of $10.1 for the year ended December 31, 2017.
[5]	Includes restructuring costs of $15.6, $10.9 and $12.2 for the years ended December 31, 2017, 2016 and 2015, respectively
[6]	During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes asset impairment charges of $1.2 attributed to D&S.
[7]	Includes asset impairment charges of $255.1 for the year ended December 31, 2015, attributed to E&C – $68.8, D&S – $2.0, and BioMedical – $184.3.
[8]	During the fourth quarter of 2017, we recorded a $4.9 loss on extinguishment of debt associated with the repurchase of $192.9 principal amount of our $250.0 2.00% convertible notes due August 2018 and refinance of our senior secured revolving credit facility.
[9]	The fourth quarter of 2017 includes a one-time $22.5 net favorable tax benefit that was recorded during the fourth quarter of 2017, which resulted from the enactment of the Tax Cuts and Jobs Act. This benefit mainly consisted of a one-time, provisional benefit of $26.9 related to the remeasurement of certain of our deferred tax liabilities using the lower U.S. federal corporate tax rate of 21%. This was partially offset by (i) a one-time, provisional charge of $8.7 related to the deemed repatriation transition tax, which is a tax on previously untaxed accumulated earnings and profits of certain of our foreign subsidiaries, and (ii) a one-time tax expense and tax benefit of $4.5 and $8.7, respectively, related to our intent to amend pre-acquisition Hudson U.S. federal tax returns.
[10]	Basic and diluted (loss) earnings per share are computed independently for each of the quarters presented. As such, the sum of quarterly basic and diluted (loss) earnings per share may not equal reported annual basic and diluted (loss) earnings per share.
[11]	Basic and diluted (loss) earnings per share are computed independently for each of the quarters presented. As such, the sum of quarterly basic and diluted (loss) earnings per share may not equal reported annual basic and diluted (loss) earnings per share.
[12]	Zero incremental shares from share-based awards are included in the computation of diluted net loss per share for periods in which a net loss occurs, because to do so would be anti-dilutive.
[13]	Zero incremental shares from share-based awards are included in the computation of diluted net loss per share for periods in which a net loss occurs, because to do so would be anti-dilutive.

XML 119 R97.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details)	12 Months Ended
Subsequent Events (Details)	Dec. 31, 2017
Subsequent Event [Line Items]
Subsequent Event, Description	We acquired 100% of the equity interests of Skaff Cryogenics and Cryo-Lease, LLC (together “Skaff”) on January 2, 2018 for an approximate purchase price of $12.5. Skaff provides quality repair service and remanufacturing of cryogenic and liquefied natural gas storage tanks and trailers and also maintains a portfolio of cryogenic storage equipment that is leased to customers for temporary and permanent needs. Skaff is headquartered in Brentwood, New Hampshire and provides services and equipment to customers in North America. Skaff’s results will be included in the D&S operating segment.

XML 120 R98.htm IDEA: XBRL DOCUMENT

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
$ in Millions

Allowance for Doubtful Accounts [Member]

Movement in Valuation Allowances and Reserves

Balance at beginning of period

$ 10.2

$ 7.0

$ 6.5

Additions - Charged to costs and expenses

Inventory Valuation Reserve [Member]

Balance at end of period

10.8

10.2

7.0

Movement in Valuation Allowances and Reserves

Balance at beginning of period

Additions - Charged to costs and expenses

11.3

5.2

^[2]

Balance at end of period

8.5

Valuation Allowance of Deferred Tax Assets [Member]

11.3

Movement in Valuation Allowances and Reserves

Balance at beginning of period

15.1

8.8

Additions - Charged to costs and expenses